*Review*

# Vitamin B$_{12}$ Metabolism: A Network of Multi-Protein Mediated Processes

Patryk Mucha [1], Filip Kus [1,2], Dominik Cysewski [3], Ryszard T. Smolenski [1] and Marta Tomczyk [1,*]

[1] Department of Biochemistry, Medical University of Gdansk, 80-210 Gdansk, Poland;
patryk.mucha@gumed.edu.pl (P.M.); kusfi@gumed.edu.pl (F.K.); rt.smolenski@gumed.edu.pl (R.T.S.)

[2] Laboratory of Protein Biochemistry, Intercollegiate Faculty of Biotechnology of University of Gdansk and Medical University of Gdansk, 80-307 Gdansk, Poland

[3] Clinical Research Centre, Medical University of Bialystok, 15-276 Bialystok, Poland;
dominik.cysewski@umb.edu.pl

[*] Correspondence: marta.tomczyk@gumed.edu.pl

**Abstract:** The water-soluble vitamin, vitamin B$_{12}$, also known as cobalamin, plays a crucial role in cellular metabolism, particularly in DNA synthesis, methylation, and mitochondrial functionality. Its deficiency can lead to hematological and neurological disorders; however, the manifestation of these clinical outcomes is relatively late. It leads to difficulties in the early diagnosis of vitamin B$_{12}$ deficiency. A prolonged lack of vitamin B$_{12}$ may have severe consequences including increased morbidity to neurological and cardiovascular diseases. Beyond inadequate dietary intake, vitamin B$_{12}$ deficiency might be caused by insufficient bioavailability, blood transport disruptions, or impaired cellular uptake and metabolism. Despite nearly 70 years of knowledge since the isolation and characterization of this vitamin, there are still gaps in understanding its metabolic pathways. Thus, this review aims to compile current knowledge about the crucial proteins necessary to efficiently accumulate and process vitamin B$_{12}$ in humans, presenting these systems as a multi-protein network. The epidemiological consequences, diagnosis, and treatment of vitamin B$_{12}$ deficiency are also highlighted. We also discuss clinical warnings of vitamin B$_{12}$ deficiency based on the ongoing test of specific moonlighting proteins engaged in vitamin B$_{12}$ metabolic pathways.

**Keywords:** vitamin B$_{12}$; metabolism; proteins; anemia; neurodegeneration

## 1. Introduction

Vitamin B$_{12}$ (cobalamin) was initially isolated in 1948 by two independent scientific teams—Folker's in the USA and Smith's in Great Britain—and identified: it was previously described as the antipernicious anemia factor [1]. Structurally, it possesses an organometallic nature, with the cyanide ion coordinated to the central cobalt atom. The primary Co ligand is surrounded by a corrin macrocycle containing four reduced pyrrole rings and seven amide side chains [2]. The precise structure varies among different corrinoids, where vitamin B$_{12}$ is the only form active in animals and humans. The pyrrols constitute the equatorial plane of the ring, which is supplemented by two axial Co-ligands: a nucleotide base firmly attached to the ring and an exchangeable external ligand, e.g., water, cyanide, and methyl- or 5′-deoxyadenosyl group (as well as a number of other nucleophiles), see Figure 1. Hydroxycobalamin and cyanocobalamin are metabolically inactive; however, upon conversion to methylcobalamin and 5-deoxyadenosylcobalamin, the vitamins attain full activity [3]. Among these exchangeable groups, water represents the weakest coordination ligand, while CN-group exhibits the strongest coordination [4].

**Figure 1.** Skeletal formula of cobalamin. R (green) = CN, HO, methyl, or 5-deoxyadenosyl, N (blue)—nitrogen, $Co^{+2}$ (pink)—cobaltous cation, O (red)—oxygen, H (grey)—hydrogen, P (orange)—phosphorus, arrows—possible bindings.

Humans cannot endogenously synthesize cobalamin and, consequently, must obtain it through dietary intake, predominantly sourced from meat, fish, dairy products, eggs, or some edible algae symbiotic with vitamin $B_{12}$-producing microorganisms. Diminished intake or impaired absorption of vitamin $B_{12}$ is usually caused by a decreased synthesis of a specific intestinal vitamin $B_{12}$-carrier Intrinsic Factor (IF), see Figure 2, and the disease manifests itself in elderly individuals or in vegans adhering to dairy and egg-free diets [5]. In herbivores, the intestinal uptake of vitamin $B_{12}$ is supported by the gut microbiota; whereas, in all carnivores and omnivores (including humans) the internal production of vitamin $B_{12}$ is of very limited importance compared to dietary sources. Not all corrinoids produced in nature find their biological function in human metabolism and some of them might even disrupt the normal metabolism of this vitamin [6]. One of the examples is Co$\alpha$-[$\alpha$-(7-adenyl)]-Co$\beta$-cyanocobamide, a corrinoid isolated from *Lactobacillus reuteri* and commonly named pseudovitamin $B_{12}$. This analog shares a structure resembling cobalamin, except for the lower cobalt ligand. In this modification, nucleotide base adenine substitutes the 5,6-dimethylbenzimidazole [7]. Even though pseudovitamin $B_{12}$ does not inhibit the uptake of vitamin $B_{12}$ in rats [8], some studies suggest that it could potentially disrupt the absorption of a physiological trace concentration of vitamin $B_{12}$ in the medium through the occupation of the vitamin $B_{12}$-transporting blood protein transcobalamin (TC, the product of gene *TCN2*) [9].

**Figure 2.** Adsorption, blood transport, and intracellular metabolism of vitamin $B_{12}$. Cbl—cobalamin, HC—haptocorrin, IF—Intrinsic Factor, TC—transcobalamin II, MRP1—multidrug resistant protein 1, ABCD4—ATP binding cassette subfamily D member protein, LMBD1—lysosomal cobalamin transport escort protein, MMACHC—methylmalonic aciduria and homocystinuria type C protein, MMADHC—methylmalonic aciduria and homocystinuria type D protein, AdoCbl—adenosylcobalamin, CH3Cbl—methylcobalamin, MCM—methylmalonyl CoA mutase, MS—methionine synthase. Created with BioRender.com.

The overall transportation chain of vitamin $B_{12}$ is roughly outlined in Figure 2. The absorption of dietary vitamin $B_{12}$ is preceded by the release of cobalamin bound to food proteins. First, gastric acid and proteases take action in the stomach. Afterward, a salivary protein called haptocorrin (HC, the product of gene *TCN1*) binds to liberated vitamin $B_{12}$. The protein moiety of the HC-vitamin $B_{12}$ complex is subsequently degraded by the proteases of the upper small intestine. Next, in the proximal ileum, cobalamin creates a complex with Cobalamin Binding Intrinsic Factor (IF), which is further recognized by certain receptors (first of all, the receptor cubam). Finally, the absorbed vitamin $B_{12}$ is released from IF and excreted into the blood, where it is captured by TC [10]. The "active" transporter TC has a fast turnover rate and, under a steady state, caries about 20% of the vitamin $B_{12}$ in the circulation [5]. The subsequent cellular uptake of vitamin $B_{12}$ involves the CD320 receptor, present in all cell types [11]. Next, the vitamin $B_{12}$-TC complex is transferred into lysosomes where the protein carrier breaks down. ATP Binding Cassette Subfamily D Member 4 protein (ABCD4, encoded by the gene of the same name) and lysosomal cobalamin transport-escort protein (LMBD1, *LMBRD1* gene) are responsible for its further transport from the lysosomal lumen to the cytosol. When cobalamin is released into the cytosol, the cytoplasmic chaperons methylmalonic aciduria and homocystinuria type C protein (CblC, gene *MMACHC*) and methylmalonic aciduria and homocystinuria type D protein (CblD, gene *MMADHC*) initiate processing of the incoming vitamin, which starts with its reduction to $Co^{2+}$ accompanied by removal of the original exchangeable group [12]. In the cytoplasm, vitamin $B_{12}$ is converted to methylcobalamin (CH3Cbl, MeCbl), while adenosylcobalamin (AdoCbl) is synthesized in the mitochondria. MeCbl acts as a carrier of methyl groups. It is a co-factor of the enzyme methionine synthase (MS, gene *MTR*), which is involved in the transformation of homocysteine to methionine in the cytosol. These processes and subsequent metabolic reactions are involved in the synthesis of neurotransmitters, phospholipids, DNA, and RNA. On the other hand, AdoCbl acts as

a cofactor of a mitochondrial enzyme, methylmalonyl-coenzyme A mutase (MCM, gene *MMUT*), which converts methylmalonyl-CoA to succinyl-CoA. This reaction is involved in the catabolism of cholesterol, fatty acids, and several amino acids [11]. The impairment of those enzymatic reactions leads to the elevation of homocysteine and methylmalonic acid, non-metabolizable end products, which is important in vitamin $B_{12}$ deficiency diagnosis.

Due to its involvement in various cellular pathways (including isolation of nerve axons and DNA synthesis), alterations in vitamin $B_{12}$ metabolism strongly correlate with cognitive impairment, hematological disorders, and cardiovascular diseases [13,14]. Thus, more in-depth research is necessary to fully elucidate the steps and compounds involved in vitamin $B_{12}$ metabolic pathways.

This review aims to comprehensively summarize all of the identified proteins essential for the proper metabolism of vitamin $B_{12}$ in humans and diseases related to its dysfunction. Furthermore, based on the collected data, we propose new diagnostic options as well as new warnings within the field of vitamin $B_{12}$ deficiency research.

## 2. Proteins Involved in Vitamin $B_{12}$ Metabolism

### 2.1. Gastrointestinal Vitamin $B_{12}$ Transport

2.1.1. Haptocorrin (HC) and Intrinsic Factor (IF)

As previously elucidated, the absorption and utilization of vitamin $B_{12}$ within the body require its initial binding to carrier proteins in the gastrointestinal tract. In humans, the two proteins facilitating this binding process are haptocorrin (HC) and Intrinsic Factor (IF). Despite their immunological distinctiveness, they exhibit structural similarities due to their primary and secondary protein structures [15,16]. In humans, parietal cells within the gastric mucosa of the ileum produce Intrinsic Factor (IF). The gene responsible for encoding IF is known as Gastric Intrinsic Factor (*GIF*) or Cobalamin Binding Intrinsic Factor (*CBLIF*), which is situated on chromosome 11 (11q12.1) in humans and on chromosome 19 in mice [17,18]. IF is made of 399 amino acid residues [16] and has a two-domain organization, with each domain having a mass of approx. 30 kDa and 20 kDa (including the conjugated sugar residues). Vitamin $B_{12}$ is bound to the two domains via multiple bonds [16].

Initially named the R-binder or transcobalamin I (TCN1), haptocorrin (HC) is the first carrier protein for ingested vitamin $B_{12}$. The investigation of the *TCN1* gene sequence and its localization suggests that HC is an evolutionary product of *CBLIF* duplication [19]. This glycoprotein of 60 to 70 kDa [16,19] is present in various body fluids including saliva, breast milk, bile, tears, and blood plasma [17,20]. Upon ingestion, vitamin $B_{12}$ is bound by HC secreted in saliva, which is responsible for transferring the free vitamin to the stomach. HC also binds dietary vitamin $B_{12}$, released from food proteins in the stomach [17]. In the acidic pH of the stomach, HC is thought to protect the vitamin from partial hydrolysis [21]. Vitamin $B_{12}$ remains bound to HC at the entrance to the duodenum, where pancreatic proteases, namely trypsin, chymotrypsin, and elastase, degrade HC, allowing for the release of vitamin $B_{12}$ and its subsequent binding by IF, which was produced in the stomach but remained incapable of binding vitamin $B_{12}$ until the acidic medium became neutralized [11]. Interestingly, deficiencies of pancreatic proteases can lead to defects in vitamin $B_{12}$ absorption due to the inability to degrade HC and release the vitamin from the vitamin $B_{12}$–HC complex. Patients with exocrine pancreatic insufficiency or chronic pancreatitis, conditions marked by inadequate delivery of pancreatic digestive enzymes to the intestine, often develop vitamin $B_{12}$ malabsorption. However, these conditions rarely lead to severe vitamin $B_{12}$ deficiency [22–24].

Studies on the exact role of HC in humans are limited due to the lack of homologous genes encoding HC in both mice and rats [25]. In these rodents, salivary glands produce another vitamin $B_{12}$-binding protein transcobalamin (TC), which in humans is responsible for binding the vitamin in blood plasma [11]. This points out that details of the binding of ingested vitamin $B_{12}$ vary between different species, where only some of them express HC [25].

After the release of vitamin $B_{12}$ from HC in the duodenum, vitamin $B_{12}$ binds to Intrinsic Factor (IF). IF is mostly found in gastric juice and ileal fluid in humans, being produced and secreted by parietal cells in the stomach. It is responsible for transferring vitamin $B_{12}$ along the small intestine to the intestinal epithelial cells, which are mainly composed of enterocytes [16,21]. When vitamin $B_{12}$ is bound to IF, its domains can be assembled. This mechanism ensures that only the IF–vitamin $B_{12}$ complex, not the apoprotein present in a high excess, can be recognized and absorbed with the help of the specific receptor cubam [15,26,27].

IF deficiency can be caused by the presence of anti-IF or anti-parietal cell autoantibodies as well as the age-dependent or autoimmune degeneration of parietal cells, e.g., autoimmune gastritis (AIG). The presence of autoantibodies is often linked to *Helicobacter pylori* (*H. pylori*) infection. Patients with *H. pylori* infection have been found to have decreased vitamin $B_{12}$ levels in serum [28]. The exact cause of AIG is still unknown and there is no treatment available. The wide range of unspecific clinical symptoms, which are often subtle (many patients are asymptomatic for a long period after the disease onset), result in difficulties in diagnosing the condition promptly [29]. The lack of IF in this condition leads to long-lasting vitamin $B_{12}$ deficiency due to the inability to deliver vitamin $B_{12}$ to the cells within the ileum and subsequent failure to distribute it throughout the body. The consequence of vitamin $B_{12}$ deficiency in AIG is pernicious anemia (PA) [11,30]. Around 10–15% of patients with AIG develop PA, characterized by hematological, neurological impairments, or both. The hematological manifestation includes megaloblastic anemia, while the clinical neurologic manifestations of PA include weakness, depression, impaired nerve function, cognitive impairment, and sensory deficits [11,31].

### 2.1.2. Cubam Receptor

When the vitamin $B_{12}$–IF complex reaches the intestine, it is internalized into enterocytes by receptor-mediated endocytosis. Cubam is a multiligand apical membrane receptor expressed in absorptive epithelia in several tissues. In the kidney, cubam is expressed in the proximal tubular epithelium where it mediates the reabsorption of proteins from the renal filtrate, such as albumin, apolipoprotein A-1, hemoglobin, transferrin, and vitamin-D binding protein, leading to reduced proteinuria [32,33]. Cubam is also present in the visceral yolk sac, where it is essential to coordinate maternal nutrient uptake and proper embryo development [34,35]. In the epithelium of the distal ileum, the only known function of cubam is to facilitate the uptake of the IF–vitamin $B_{12}$ complex [33].

Cubam is composed of two proteins: cubilin (CUBN) and type-1 transmembrane protein amnionless (coded by gene *AMN*). Cubilin is a 460 kDa protein that contains three distinct regions: an N-terminal domain, responsible for membrane association; an extracellular fragment formed by epidermal growth factor-like repeats; and 27 domains of complement components C1r/C1s, epidermal growth factor-related protein 1 (Uegf), and bone morphogenetic protein 1 (Bmp1), CUB [36]. Four CUB domains, $CUB_{5-8}$, are responsible for the interaction with the IF–cobalamin complex, as revealed by crystal structures [37]. The remaining domains are involved in the recognition and binding of other ligands, for example, during ultrafiltration and reabsorption in the kidney [38]. To form a receptor, three CUBN-subunits combine in a pin-shaped molecule that docks to transmembrane protein AMN. Cubilin lacks a transmembrane domain and, therefore, the interaction with amnionless is necessary for the formation of a functional cubam complex [32].

AMN-protein is a 45-kDa transmembrane protein also composed of three parts: an extracellular domain, a transmembrane helix, and a cytoplasmic domain responsible for clathrin-mediated internalization. In addition to anchoring CUBN-protein to the apical membrane of epithelia, amnionless is also required for biosynthetic processing and trafficking of cubilin to the plasma membrane. It also mediates cubam receptor recycling and endocytic signaling [39]. The cytoplasmic domain of amnionless features two putative FXNPXF endocytic signals that closely resemble the FXNPXY signal found in the low-density

lipoprotein receptor (LDLR) superfamily. The related signaling involves clathrin-associated sorting of proteins (CLASPs) and promotes the clathrin-dependent internalization of various cubam ligands in an analogous way to the internalization of LDLRs [33]. The LDLR family also includes the protein Megalin, which strongly colocalizes with cubam, especially in the kidney where they cooperate in ligand recognition. However, in the intestine, cubam appears to be functioning independently of Megalin, suggesting that only AMN and CUBN protein moieties are required to form a receptor specific for IF–vitamin $B_{12}$ internalization [40].

Mutations in either of the *CUBN* or *AMN* genes disrupt cubam receptor functioning and result in malabsorption of vitamin $B_{12}$ and the development of Imerslund–Gräsbeck syndrome (IGS). IGS is a rare autosomal recessive disorder that appears in childhood. It is characterized by megaloblastic anemia as a consequence of vitamin $B_{12}$ deficiency [41]. Most IGS patients also develop mild proteinuria and non-specific symptoms attributed to vitamin $B_{12}$ deficiency [42], even though, if left untreated, the disease may result in neurological impairments and can be fatal. Treatment with parenteral vitamin $B_{12}$ therapy, typically via regular intramuscular injections, is effective in managing the condition [43,44]. Recent data also demonstrate altered expression of amnionless in the kidney and the ileum with aging. This causes vitamin $B_{12}$ deficiency irrespectively of its normal nutritional uptake as well as the development of age-related chronic diseases [45].

### 2.1.3. Multidrug Resistant Protein 1 (MRP1)

Upon the uptake to the enterocyte, the next step in vitamin $B_{12}$ transport is its distribution to other cells and tissues in the body. To achieve this, vitamin $B_{12}$ needs to be exported into the blood circulation and this step is mediated by multidrug resistant protein 1 (MRP1, gene *ABCC1*).

MRP1 has been described for the first time, in 1992 by Cole et al. This 190 kDa glycoprotein that has been shown to export a wide range of substrates including bioactive compounds, signaling molecules, metabolites, anti-cancer drugs, and xenobiotics, thus conferring multidrug resistance in cancer. For example, MRP1 is overexpressed in many hematological and solid tumors [46,47]. Under physiologic conditions, MRP1 is ubiquitously expressed in the body, mostly in the lung, testis, kidney, heart, placenta, small intestine, colon, brain, and peripheral blood mononuclear cells [47–49]. In the small intestine, MRP1 is mainly present in the basolateral membranes of the crypt cells [50]. In addition to the plasma membrane localization, MRP1 has also been shown to accumulate in subcellular organelles such as endocytic vesicles, trans-Golgi vesicles, and lysosomes [48,51], although its involvement in the intracellular transport of vitamin $B_{12}$ has never been demonstrated. MRP1, similarly to lysosomal vitamin $B_{12}$ exporter ABCD4, also belongs to the ABC transporters family, hence its alternative name ABCC1 [46].

MRP1 has been shown to efflux vitamin $B_{12}$ from the intestinal epithelium to the blood circulation [52]. Mice deficient in MRP1 ($MRP1^{(-/-)}$) have decreased levels of vitamin $B_{12}$ in their plasma, simultaneously accumulating the vitamin in the ileum and colon. These studies also established that MRP1 transports the vitamin in its protein-free form, contrary to the previously hypothesized export of the vitamin in complex with transcobalamin [52,53]. In some patients with recessive hereditary vitamin $B_{12}$ malabsorption, mutations in the MRP1-encoding gene *ABCC1* were detected; however, they were ruled out as potential causes of vitamin $B_{12}$ deficiency as they either appeared in the intronic gene fragments, which did not affect the open reading frame, or did not fulfill Mendelian rules for inheritance [54]. These studies were conducted on a small group (approx. 30) of patients, suggesting a need for large-scale epidemiological investigation to clarify the involvement of *ABCC1* mutations in the development of vitamin $B_{12}$ deficiency. Such investigations could potentially validate the redundancy in vitamin $B_{12}$ export given the existence of alternative pathways aside from MRP1 export in humans. Among other closely related transporters of the ABC family with wide tissue distribution (ABCB6, ABCG2, MRP3, and MRP5), only MRP1 was shown to be involved in vitamin $B_{12}$ efflux [52]. Moreover, as presented by Beedholm-Ebsen et al.,

$MRP1^{(-/-)}$ mice have not presented morphologic and metabolic abnormalities, suggesting that other transporters should compensate for the lack of MRP1 (also considering a passive transport of vitamin $B_{12}$ through membranes herein).

## 2.2. Proteins Involved in Vitamin $B_{12}$ Blood Transport

Transcobalamin (TC)

When vitamin $B_{12}$ is exported into the blood circulation, it is bound by a 43 kDa protein transcobalamin, a former transcobalamin II (gene *TCN2*) [55]. In humans, TC is synthesized by a variety of cell types and tissues and secreted to blood plasma [56,57]. TC is structurally related to IF and HC, with some conserved regions sharing 60–80% homology; all three vitamin $B_{12}$ transporters are derived from a common ancestral gene [53,58]. TC is responsible for the distribution of vitamin $B_{12}$ into all of the cells in the body but only about 25% of the total vitamin $B_{12}$ in plasma is bound by TC, while the rest is carried by circulating HC [59,60]. The complex of vitamin $B_{12}$ and transcobalamin is referred to as holoTC and is the "active" form of vitamin $B_{12}$ with a fast turnover rate, making vitamin $B_{12}$ available to cells. In contrast, the biological function of the complex with HC (holoHC) is not clear [21].

HoloTC levels in serum have been suggested as a specific marker of early vitamin $B_{12}$ deficiency diagnosis with the use of commercially available immunoassays for holoTC [61]. However, some studies indicate that this is a controversial determinant of vitamin $B_{12}$ status. Some patients with severe vitamin $B_{12}$ deficiency, resulting in PA, displayed falsely normal holoTC levels [62]. It was also hinted that the rationale behind the diagnostic holoTC immunoassay is based on a false assumption that holoTC is the first factor to respond to vitamin $B_{12}$ deficiency, where the level of methylmalonic acid (MMA), a form of substrate for methylmalonyl-CoA mutase that requires vitamin $B_{12}$ as a cofactor, and is more sensitive to vitamin $B_{12}$ deficits in the early stage [63,64].

Mutations in the *TCN2* gene can hamper or even prevent intracellular accumulation of cobalamin, causing a rare multisystemic disorder characterized by autosomal recessive inheritance with symptoms such as pancytopenia, megaloblastic anemia, developmental delay, diarrhea, psychomotor impairment, and immune system deficiency [65]. Only a few cases have been investigated so far, showing either a large deletion of the entire exon 8 leading to a premature stop codon (p.E371fsX372) [66] or a change in intron 4 leading to the loss of the start codon as a cause of gene alternation [67].

## 2.3. Proteins Involved in Intracellular Vitamin $B_{12}$ Transport

### 2.3.1. CD320 Receptor

CD320, also known as the receptor for cobalamin-saturated transcobalamin (TCblR), is a small 282 amino acid protein with 29 kDa calculated molecular weight (observed 58 kDa, probably due to a high glycosylation) [68]. It belongs to the LDLR protein family. CD320 is localized on the cell surface and contains two domains connected by the transmembrane helix. These are the C-terminal cytoplasmic region and the extracellular N-terminal fragment with an epidermal growth factor (EGF) separating the two LDLR type A sites [69,70]. A soluble form (sCD320) was also found in the human serum fraction [71]. CD320 exhibits high specificity and affinity toward transcobalamin and the TC–cobalamin complex is bound to CD320 and absorbed by the cells in the presence of $Ca^{2+}$ ions [72,73]. Initially, holo-TC binds to the N-terminal region of CD320 whereupon it is internalized into an endocytic vesicle. Next, endosomes with holo-320 complexes are fused with a lysosome, where TC and CD320 undergo dissociation and degradation. Subsequently, cobalamin is freed into the cytoplasm [74].

During the process in which holo-TC uptake receptors are broken down, the occurrence of CD320 on the cell surface is the direct result of its synthesis [75]. The level of the CD320 receptor is highly associated with the cell-division cycle and its presence on the cell surface is high in fast-growing cells, including cancer cells [74]. The impact of CD320 deficiency was tested in animal models with CD320 knock-out (KO) mice fed with a vitamin $B_{12}$

deficient diet. Those animals showed increased MMA and homocysteine levels in the serum, as well as macrocytic anemic phenotype [76]. Neutrophil hypersegmentation is usually also a clinical hallmark of cobalamin uptake failure in patients [77]. Moreover, female mice with CD320 depletion and limited cobalamin intake exhibited infertility. Even though supplementation with cyanocobalamin resulted in a successful pregnancy, all litters died just after birth [76]. Other studies indicate that the knockdown of CD320 caused cognitive and learning disorders along with anxiety behavior corresponding to symptoms observed in humans, pointing out direct changes in the central nervous system [78]. It is suggested that observed alternation of DNA methylation in CD320 KO mice brains might cause neuron demyelination [79].

A single nucleotide polymorphism of CD320, rs2336573, leading to a glycine-to-arginine change has been identified in patients with lowered serum vitamin $B_{12}$ levels [80]. Analogous outcomes occurred at a single codon deletion of c.262_264GAG (p.E88del). These observations have been linked with an increased MMA concentration in newborns [81]. However, in 2022, Pangilinan et al., using population data, estimated that approximately 85% of p.E88del homozygotes born in the same period did not have elevated propionylcarnitine (C3), suggesting that cobalamin metabolism in the majority of these infants with this genotype is unaffected. Thus, more studies are required to clarify the natural history of various *CD320* variants across patient populations [82].

### 2.3.2. ATP Binding Cassette Subfamily D Member 4 (ABCD4) and the Lysosomal Cobalamin Transport Escort Protein (LMBD1)

Free vitamin $B_{12}$ is released into the cytoplasm by an ATP (adenosine-5′- triphosphate) Binding Cassette Subfamily D Member protein (ABCD4, encoded by the gene of the same name), a 68.6 kDa exporter located on the lysosomal membrane [83]. ABCD4 consists of a transmembrane domain and a nucleotide-binding domain, which is involved in binding and hydrolysis of ATP [84]. It belongs to the family of ATP-binding cassette (ABC) transporters that mediate the transport of various substrates across the cell membrane against the concentration gradient. Most of the human ABC exporters are localized in a way that allows the substrate to access from the binding site, in a *cis*-acting manner. As revealed by cryo-electron microscopy (EM) studies, ABCD4 is a unique exporter, facilitating transfer in a *trans*-acting manner, thus allowing the transfer of vitamin $B_{12}$ from the lysosome to the cytoplasm [85].

ABCD4 is a membrane endoplasmic reticulum (ER)-resident protein and requires translocation from the ER to the lysosome to facilitate vitamin $B_{12}$ release. ABCD4 was found to colocalize with a 61.4 kDa membrane lysosomal cobalamin transport escort protein (LMBD1, encoded by gene *LMBRD1*), which localizes primarily to lysosomes [83,86]. Initially, LMBD1 was suggested to act as a lysosomal exporter of vitamin $B_{12}$ [87]. However, later findings demonstrated that LMBD1 acts as an adaptor protein and mediates the translocation of ABCD4 from ER to the lysosomes [88]. Both proteins function in a coordinated manner and form a complex, as demonstrated by Surface Plasmon Resonance (SPR) [86].

Mutations in *ABCD4* and *LMBDR1* genes cause disease group cobalamine J and F diseases (cblJ, cblF), respectively [83,87]. At the cellular level, both errors are marked with a decreased function of methylmalonyl-CoA mutase and methionine synthase and an accumulation of free vitamin $B_{12}$ in the lysosomes [89]. However, up to date, there is no clear biochemical or clinical distinction between cblJ and cblF. Only molecular genetic testing, either gene-targeted (RNA-sequencing and single-gene testing) or comprehensive (e.g., exome sequencing), was successfully applied to confirm each of the defects [90–92]. There is a wide spectrum of clinical presentations in both diseases, which may include hampered growth, developmental delay, developmental abnormalities progressive hyper-pigmentation, cardiac defects, and hematologic impairments (such as macrocytic anemia, neutropenia thrombocytopenia, and pancytopenia). Neurological presentations may include general weakness, dizziness, delayed motor development, and mild intellectual disability [83,87,90,93].

### 2.3.3. Methylmalonic Aciduria and the Homocystinuria Type C Protein (MMACHC)

Cobalamin that is released from lysosomes into the cytosol is available for two cytoplasmic proteins—methylmalonic aciduria and homocystinuria type C protein (MMACHC or CblC, encoded by *MMACHC* gene) and type d protein (MMADHC or CblD, encoded by *MMADHC* gene). The analysis of individuals with inborn errors of cobalamin metabolism revealed that the *MMACHC* gene is localized to the 1p34.1 region of chromosome 1 and consists of five exons. A study by Wang et al. suggested that c.609G > A, c.658_660delAAG, c.80A > G, and c.482 G > A mutations were the most common mutations in the Chinese population, while the most frequent mutations in the Caucasian population were c.271dupA, c.394C > T, and c.331C > T [94,95]. The *MMACHC* gene product consists of 282 amino acids and has a mass of 31.7 kDa [96]. *MMACHC* manifests a substantial degree of evolutionary conservation across mammalian species and exhibits high expression levels in the fetal liver, with its presence also identified in a broad spectrum of tissues, including the spleen, thymus, and bone marrow [96].

The *MMACHC* gene encodes a protein possessing both chaperone and enzyme functionalities. Its inactivation disrupts the reduction in incoming cobalamin molecules, which is necessary for the following synthesis of two essential cobalamin forms: methylcobalamin (MeCbl) and adenosylcobalamin (AdoCbl), which are cofactors for enzymes dependent on vitamin $B_{12}$ [97]. The defects in MMACHC impact a stage occurring after the cellular absorption of cobalamin but preceding the synthesis of AdoCbl and MeCbl [96]. MMACHC catalyzes the reductive decyanation of cyanocobalamin (CNCbl or vitamin $B_{12}$ in conjunction with a flavoprotein oxidoreductase) [98]. Interestingly, CblC also exhibits the remarkable capability to catalyze the nucleophilic displacement of the alkyl group by glutathione when presented with an alkylcobalamin. However, different forms of cobalamin are processed with a different efficacy by the intracellular system of enzymes and chaperons (e.g., better for GSCbl in comparison to other Cbl-forms [99]). This leads to considerable variation in the rates of the intracellular accumulation of those Cbls and, consequently, to different rates of the coenzyme appearance as established for HOCbl and CNCbl [100]. The intricate protein–protein interaction between MMACHC and MS is widely acknowledged for its pivotal role in regulating intracellular cobalamin metabolism. Notably, the interaction of MS inactive isoforms impedes MMACHC activity [101]. MMCHC is also essential in the conversion of MMA to succinyl-CoA [98].

Mutations in the *MMACHC* gene can result in a rare genetic disorder referred to as methylmalonic aciduria and homocystinuria type C (cblC). They demonstrate deficiencies in both vitamin $B_{12}$-dependent enzymatic functions crucial in mammals—MS and MUT [98]. Thus, this disorder is characterized by the accumulation of both MMA and homocysteine (Hcy) in serum [98]. Individuals affected by the cblC disorder manifest severe neurological and systemic metabolic abnormalities [97], such as atypical hemolytic uremic syndromes (aHUS), decline in renal function, idiopathic neuropathies, spinal cord degenerations, ataxias, recurrent thrombosis, visual field defects, maculopathy, and optic disc atrophy [102]. Interestingly, recent studies suggest that the involvement of cobalamin and MMACHC might have a potential role in the oncogenic transformation of specific tumor subtypes. Melanomas and cell lines derived from melanoma often exhibit a higher occurrence of elevated methylation in the *MMACHC* promoter compared to other cancer types. This fact implicates the inactivation of *MMACHC* as the causative factor [97,103]. However, Bauer et al. highlighted that the defect in metabolism observed in MeWo-LC1 was unique and that decreased *MMACHC* expression was not a cause of methionine dependence in the other melanoma lines [104].

### 2.3.4. Methylmalonic Aciduria and the Homocystinuria Type D Protein (MMADHC)

The *MMADHC* gene is associated with methylmalonic aciduria type D and homocystinuria and it is classified within the cblD complementation group [105]. The *MMADHC* gene encodes a protein consisting of 296 amino acids, with a molecular weight of 32.9 kDa. The MMADHC protein (also called CblD protein) exhibits a high degree of conservation

across various mammalian species. The *MMADHC* gene encodes a robust N-terminal mitochondrial leader sequence along with a conserved vitamin B$_{12}$-binding motif located at residues 81–86 [105]; however, a recent study has also shown cobalamin binding to a different region of the MMADHC protein [106]. It is present in both the mitochondria and cytoplasm, although the precise mechanisms that lead to this dual localization are not fully understood. The analysis of *MMACHC* and *MMADHC* gene expression patterns during mouse development unveils overlapping expression, particularly evident in the developing cardiac, respiratory, and nervous systems. It is suggested that these two proteins are co-expressed in all cells, as there is no discernible specificity for any particular organ, tissue, or cell type exclusively expressing *MMADHC*. Notably, *MMADHC* demonstrates expression in all cells of embryos, including those expressing *MMACHC* [107].

The physiological function of MMADHC is yet to be fully understood; however, it seems to play a role in the delivery of the cobalamin precursor to either cytoplasmic or mitochondrial sites of the production of the two active cobalamin forms, MeCbl and AdoCbl [108]. Plesa et. al., in 2011, employed a phage display to predict regions on MMADHC that bind to MMACHC. The study identified five distinct regions on MMADHC, with all aligning with residues C-terminal to Met116 [109] but not with the N-terminus (residues 1–61) [110]. MMADHC lacks any recognized enzymatic activity and it is suggested to be the first protein identified to repurpose the nitroreductase fold exclusively for protein–protein interactions [111].

The cblD complementation group can be linked to isolated methylmalonic aciduria (cblD-MMA), isolated homocystinuria (cblD-HC), or a combination of both methylmalonic aciduria and homocystinuria (cblD-MMA/HC) [112]. Individuals characterized by cblD-MMA have at least one altered allele that induces a premature stop codon in the N-terminal region of the protein. In contrast, those with cblD-HC possess at least one missense mutation, resulting in amino acid substitutions located in the C-terminal part of the protein [108]. The clinical presentation indicates that patients with cblD-MMA/HC and cblD-HC exhibit neurological and hematological symptoms. In contrast, cblD-MMA patients experience respiratory distress, hyperammonemia, and neurological symptoms [105,112,113].

*2.4. Vitamin B$_{12}$-Dependent Intracellular Enzymes*

2.4.1. Methionine Synthase (MS)

Methionine synthase (MS, encoded by gene *MTR*) is a big ~140 kDa monomeric protein found in the cytosol [114] and it consists of four domains. In bacteria, the N-terminal site, dependent on the zinc ions, binds and activates Hcy while the following domain has a high affinity to methyltetrahydrofolate and might affect its activity [115,116]. The third module is vitamin B$_{12}$-dependent and crucial in methyl group transfer from 5-methyltetrahydrofolate to Hcy with the production of tetrahydrofolate and methionine [116]. Finally, the C-terminal domain binds S-adenosylmethionine for reductive activation of MS [117], when cobalamin cofactor undergoes oxidation process [117]. The human enzyme displays a 58% identity with MS from *Escherichia coli* (*E. coli*) [118], which is one of the biggest proteins with 1227 residues and a molecular weight of ~136 kDa [119]. The remarkable conservation of amino acid residues across proteins indicates a high degree of similarity in properties and structures between enzymes from both humans and *E. coli*. Consequently, the information gleaned from the *E. coli* enzyme is presumed to apply to its human counterpart [118]. However, a crucial divergence is the lack of flavodoxin in mammals, a pivotal component in the reductive reactivation process observed in bacterial models [120].

In mice models, full depletion of the *MTR* gene caused pregnancy failure [114]. In proliferating cells of the skin and intestinal epitheliums, as well as in rat intestine crypts and proliferating Caco-2 cells (human epithelial colorectal adenocarcinoma cell line), there is a consistent increase in the transcription, protein expression, and activity of MS. Additionally, MS activity correlates with DNA methylation in rat intestine villi [121]. Moreover, in situ hybridization indicated that the human *MTR* gene is found on the 1q43 chromosome region [118] and its missense mutation or deletion of three base pairs was identified in the

cblG group of patients with cobalamin metabolism disorder [122]. However, the second form of this disorder has also been recognized as "methylcobalamin deficiency cblE type" (cblE) and it is believed to arise from mutations occurring at distinct genetic loci [123]. This rare autosomal disease is associated with homocysteinemia, homocystinuria, and hypomethioninemia [122] and patients usually exhibit symptoms within the initial two years of their lives [124]. Reduced MS activity also leads to an elevation in the catalytic protein phosphatase 2A (PP2A), resulting in an imbalance in the phosphorylation/methylation of nucleocytoplasmic RNA binding proteins. This leads to compromised energy metabolism and neuroplasticity linked to inborn errors of Cbl metabolism (IECM) [125].

### 2.4.2. Methylmalonyl-CoA Mutase (MCM)

Methylmalonyl coenzyme A mutase (MCM, encoded by gene *MMUT*) is an enzymatic protein found in mitochondrial matrix with a ~78 kDa molecular weight [126]. The structure of MCM is highly conserved evolutionarily; thus, this AdoCbl-dependent enzyme may be found in both eukaryotes and prokaryotes [126] but not plants [127]. MCM takes part in converting carbon skeletons of odd-chain fatty acids, cholesterol, and amino acids such as threonine, methionine, valine, and isoleucine into succinyl-CoA for further utilization in the tricarboxylic acid (TCA) cycle [128].

It has to be mentioned that the proper MCM activity depends on AdoCbl, the synthesis of which involves chaperones encoded by the *cblA* and *cblB* genes. The *cblA* gene encodes a GTPase methylmalonic aciduria type A (MMAA) and *cblB* encodes adenosyltransferase (ATR), with each playing unique roles in cofactor assimilation, loading, and repair of MCM [126]. ATR, also known as MMAB for its role in methylmalonic aciduria type B, is a multifunctional protein acting as both an enzyme and a chaperone in mitochondrial transport [129]. Its adenosyltransferase activity converts inactive cobalamin into AdoCbl and inorganic triphosphate in the presence of a reductant and ATP. Some studies show that inactivation of MCM occurs when AdoCbl is oxidized to HOCbl [130]. The inactivation of MCM occurs when the active adenosyl radical generated during the enzyme catalytic cycle reacts with a molecule other than the substrate, inactivating the enzyme. However, the formation of the MMUT-methylmalonic aciduria type A (MMAA) protein complex with MCM reduces the rate of oxidized cofactor formation, protecting enzyme activity. In detail, the enzyme is inactivated until the damaged cobalamin is removed and replaced by MMAA [131].

Human MCM is encoded by the *MMUT* gene, situated as a lone copy on chromosome 6 (6p21.3), and composed of 13 exons [132]. Its mutation leads to methylmalonic acidemia—a metabolic autosomal disease. Patients with acidemia suffer from vomiting followed by dehydration, muscle weakness, lethargy, mental incapacity, and, rarely, to death when not treated [133].

Two subgroups of MCM mutation have been recognized so far: the $mut^-$ defect, characterized by residual activity in the presence of high concentrations of AdoCbl, and the $mut^0$ defect, with complete loss of MCM activity [134]. Distinguishing between $mut^-$ and $mut^0$ subgroups can be challenging at times. Certain $mut^-$ mutations may only impact the apparent Michaelis constant ($K_m$), while others can influence both the apparent $K_m$ and the maximum velocity of an enzymatic reaction ($V_{max}$) [133].

### 3. Vitamin B$_{12}$ Deficiency

#### 3.1. Epidemiology and Symptoms of Vitamin B$_{12}$ Deficiency

The prevalence of vitamin B$_{12}$ deficiency in the United States (US) ranges from 2% to 15%, depending on the biomarker (e.g., total/active vitamin B$_{12}$ metabolites or combined index of vitamin B$_{12}$ status) and its cut-off used, as well as on the age, gender, and ethnicity [135,136]. An analysis of National Health and Nutrition Examination Survey data from 2007 to 2018 revealed that about 3.6% of all adults aged 19 and older have a vitamin B$_{12}$ deficiency (in the US, it is defined as serum vitamin B$_{12}$ levels below 200 pg/mL (148 pmol/L)). The deficiency rate increases to 3.7% in individuals aged 60 and older. How-

ever, vitamin $B_{12}$ insufficiency (defined as serum levels below 300 pg/mL (221 pmol/L)) is more prevalent, affecting approximately 12.5% of all adults aged 19 and older and 12.3% of those aged 60 and older [137]. During pregnancy, serum vitamin $B_{12}$ levels often decline, sometimes dropping to subnormal levels, but typically return to normal after delivery [138]. Furthermore, vitamin $B_{12}$ deficiency due to pernicious anemia is more common in people of northern European ancestry than people of African descent [139,140].

Food-bound cobalamin malabsorption (FBCM) is among the frequent causes of vitamin $B_{12}$ deficiency [141]. FBCM is characterized by a hindered liberation and absorption of cobalamin from food sources [142]. Impaired release of cobalamin from its gastrointestinal transport proteins is commonly seen in conditions like gastritis or during medication use, reducing hydrochloric acid production. Milder symptoms may persist due to impaired IF-dependent transport functionality [143]. Proton pump inhibitors and histamine H2-receptor antagonists heighten the risk of future cobalamin deficiency, while cessation of medication reduces the risk. For example, the widespread use of acid-suppressing medications may lead to undiagnosed cobalamin deficiency [144].

The effects of vitamin $B_{12}$ deficiency are mainly seen in the blood and nervous system. Thus, the classic manifestation was first identified as pernicious anemia [145]. Since then, the spectrum has shifted considerably, starting with the recognition that neurological manifestations (ataxia, cognitive decline leading to dementia, or psychiatric disorder) often predominate and can occur in the absence of hematological disorders [146]. Anemia is caused by disruption of DNA synthesis in a hematopoietic system, predominantly erythroid precursors. It is caused by a "folate trap", i.e., when the low activity of MS (caused by a low MeCbl coenzyme level) is not sufficient to liberate free tetrahydrofolate from its inactive methyl-complex. Neurological complications are associated with impaired methylation of myelin lipids caused by insufficient production of S-adenosyl methionine (mediated by MeCbl). Such insufficiency damages the isolating myelin sheath of axons [31,147,148]. Moreover, lack of MeCbl or MTR inhibition leads to hyperhomocysteinemia linked with inflammation, oxidative stress, and microvascular disease that may exacerbate neurological symptoms [149].

In addition to the symptomatic presentation of vitamin $B_{12}$ deficiency, subclinical cobalamin deficiency (SCCD) presents a condition characterized by biochemical aberrations in the absence of clinical signs [141,150]. SCCD is encountered more commonly than the overt deficiency and it often originates from FBCM [151,152]. Currently, SCCD is perceived as a transient state without overt cobalamin depletion, necessitating exploration into remediable etiologies. Patients exhibiting serum cobalamin levels between 110 and 148 pmol/L should be reexamined by other markers to the test (e.g., MMA) and undergo retesting within one to two months; those exhibiting normalization need not undergo further assessment [153]. Persistent low levels may warrant low-dose oral cobalamin supplementation alongside anti-IF antibody analysis. Neurological manifestations should prompt reassessment by a healthcare provider. Positive anti-IF antibody titers necessitate treatment for pernicious anemia, while negative results mandate reevaluation after three to four months [154]. Additional biochemical assessments are warranted if cobalamin levels remain consistently low.

## 3.2. Diagnosis and Treatment of Vitamin $B_{12}$ Deficiency

The assessment of vitamin $B_{12}$ status typically relies on measurements of its serum or plasma levels. Laboratories often define subnormal values as below 200 or 250 pg/mL (148 or 185 pmol/L). Typically, a value significantly below the lower limit of the reference range suggests probable vitamin $B_{12}$ deficiency, while a value well above probably indicates its adequate status. However, exceptions arise in patients with pernicious anemia who have circulating antibodies against IF; their vitamin $B_{12}$ levels may appear falsely normal despite deficiency, supposedly because of the immunological interference from anti-IF antibodies with the test setup [155]. Active vitamin $B_{12}$ bound to transcobalamin (holotranscobalamin) theoretically offers increased sensitivity for detecting vitamin $B_{12}$ deficiency compared

to total serum vitamin $B_{12}$ levels. Although the measurement of holotranscobalamin is gradually becoming available in clinical settings, it has demonstrated only marginal improvement over total vitamin $B_{12}$ levels as a biomarker for deficiency [156,157].

Another valuable and highly sensitive marker of vitamin $B_{12}$ status is the serum MMA level, with a threshold greater than 0.271 µmol/L indicative of deficiency [11]. However, MMA levels can be elevated due to renal insufficiency and tend to be higher in older adults. Genetic influences on MMA cutoffs have also been highlighted by genome-wide association studies. A common polymorphism (rs291466) in *HIBCH*, involved in valine catabolism, is prevalent (minor allele frequency 0.43) and homozygotes for the allele show 46% higher plasma MMA levels that potentially impact its efficacy of this metabolite as a vitamin $B_{12}$ status indicator [158]. Besides MMA concentration, total plasma Hcy levels also rise rapidly to levels above 15 µmol/L, with declining vitamin $B_{12}$ status. However, Hcy levels lack specificity, being influenced by factors such as folate levels or renal function decline [159]. To overcome these challenges, different combinations of the aforementioned markers are frequently used in analysis [160] and references.

Other biochemical parameters that might be useful in diagnosing vitamin $B_{12}$-related disorders include methionine. Indeed, in remethylation disorders, methionine levels might be suppressed but, more frequently, they remain stable. Thus, measuring methionine may help differentiate remethylation disorders from classical homocystinuria in cases with elevated Hcy [161]. Remethylation defects are linked with impaired remethylation of homocysteine to methionine and thus lead to the accumulation of homocysteine and perturbation of numerous methylation reactions [162]. All genetic remethylation defects result in reduced methionine synthase activity due to various factors: decreased function of the enzyme itself or its associated enzyme, methionine synthase reductase; insufficient production of the cofactor methylcobalamin; or disrupted availability of the substrate methyl-tetrahydrofolate (MTHF) [163]

Optimal management of vitamin $B_{12}$ deficiency requires identifying its cause, particularly differentiating between its low intake and malabsorption. The Schilling test, once the gold standard, is now rarely used due to the lack of radiolabeled vitamin $B_{12}$ availability and cost constraints. The CobaSorb test, measuring serum holotranscobalamin levels of post-vitamin $B_{12}$ dosing, is another opportunity [164–166]. Other tracers (e.g., low radioactive $^{14}$C- and nonradioactive $^{13}$C-labeled vitamin $B_{12}$) are currently discussed as feasible alternatives to $^{57}$Co-labeled vitamin $B_{12}$ of the Schilling text [167,168]. Alternative diagnostic approaches include detecting autoantibodies for pernicious anemia and assessing for atrophic gastritis during upper endoscopy [169]. While a negative result for anti-IF autoantibodies does not exclude pernicious anemia, a positive result is highly specific. However, a positive result for anti-$H^+/K^+$ ATPase autoantibodies lacks specificity, as it may occur in patients without pernicious anemia [170,171]. In pediatric cases, consideration of inborn errors of cobalamin metabolism via complementation phenotyping or genetic analysis is crucial for diagnosis. These tests help differentiate between different genetic causes, aiding in tailored treatment approaches for children with vitamin $B_{12}$ deficiency [12,172].

Treatment for vitamin $B_{12}$ deficiency varies depending on the underlying cause. In 2021, The British Society for Haematology (BSH) updated guidance on vitamin $B_{12}$ replacement [173]. For non-diet-related deficiency, such as in pernicious anemia or other conditions, hydroxocobalamin 1 mg intramuscular every 2–3 months for life is recommended, though the optimal time intervals might significantly vary from patient to patient. For diet-related deficiency, individuals can either orally intake cyanocobalamin (50–150 micrograms daily) between meals or receive a twice-yearly hydroxocobalamin 1 mg injection. In cases of dietary deficiency, treatment duration may vary, with vegans potentially requiring lifelong treatment.

### 3.3. Long-Term Consequences of Vitamin $B_{12}$ Deficiency

Vitamin $B_{12}$ deficiency, owing to its pivotal role in cellular metabolism, can mimic a diverse array of clinical presentations as listed above. However, a manifestation of these

clinical outcomes is relatively late. It results in the development of SCCD, which may have severe consequences, including increased risk of neurodegenerative and cardiovascular diseases or, possibly, enhanced cancer progression due to the accumulation of MMA according to [174].

In vegetarians, deficiency of vitamin $B_{12}$ was mostly found to be associated with depression and adverse neurological function. Berkins et al. highlighted that the dietary intake of vitamin $B_{12}$ might affect brain structure [175]. Interestingly, supplementation of vitamin $B_{12}$ along with anti-depressant therapy greatly improved depressive symptoms [176]. Other studies conclude that cobalamin deficiency may have some similarities with multiple sclerosis. In both conditions, destroyed myelin sheaths release glutamate, which is known to possess exotoxicity [177]. It is well known that cognitive decline often coincides with a high prevalence of vitamin $B_{12}$ deficiency, although causality in these correlations is not fully established [178]. Furthermore, while the actual percentage of reversible dementia in individuals with vitamin $B_{12}$ insufficiency is deemed low, impaired vitamin $B_{12}$ metabolism could potentially serve as one of several factors influencing the onset and progression of cognitive decline and dementia [179]. It could be caused by reduced methylation capacity, elevated Hcy levels, and the role of B vitamins in upholding the integrity of the blood–brain barrier [180]. Some researchers propose that it may act as a predisposing factor for Alzheimer's disease [181]. Additionally, it is associated with various other neurological conditions including Wernicke's encephalopathy, subacute combined degeneration of the spinal cord, and peripheral neuropathy [182].

It is well known that hyperhomocysteinemia, strongly linked to vitamin $B_{12}$ deficiency, is a prominent risk factor for atherosclerotic vascular diseases affecting coronary, cerebral, and peripheral vessels, as well as arterial and venous thromboembolism [183]. The adverse effects of Hcy on the vascular endothelium and coagulation cascade, along with its procoagulant properties, encompass reduced binding of antithrombin III to endothelial heparan sulfate, heightened affinity between lipoprotein (a) and fibrin, increased tissue factor activity in endothelial cells, and inhibition of factor V inactivation by activated protein [184]. Supplementation with vitamin $B_{12}$ led to the resolution of both clinical and biological abnormalities in all participants [185]. However, whether vitamin $B_{12}$ deficiency directly influences thrombosis or acts through hyperhomocysteinemia or other factors remains to be fully understood [186]. Lifestyle factors like smoking, BMI, and physical activity may also contribute to the association between hyperhomocysteinemia and thromboembolism [187].

Interestingly, other compounds that are strongly linked to vitamin $B_{12}$ deficiency (e.g., MMA) have been recently identified as oncometabolites. MMA is a metabolite of methylmalonyl coenzyme A; its level is increased because of impaired conversion to succinyl coenzyme A mediated by a coenzyme form of vitamin $B1_2$ (AdoCbl) [188]. A study published in 2020 by Gomes et al. revealed that MMA levels increase in the serum of older individuals and may have a function as a mediator of tumor progression. Indeed, treatment of adenocarcinoma human alveolar basal epithelial (A549) cells with MMA induced a complete pro-aggressive epithelial to mesenchymal transition-like phenotype with a decline in E-cadherin and a concurrent increase in fibronectin and vimentin [174]. Additionally, two years later, Gomes et al. demonstrated that the accumulation of MMA accelerates cancer cell aggressiveness in breast and lung cancers [174,189]. Intriguingly, in the context of breast cancer, the blockade of other metabolic pathways involving MMA or the activation of MMA production, coupled with vitamin $B_{12}$ intracellular deficiency, resulted in enhanced tumor metastasis [174,189]. Recently, MMA was also found to promote metastasis in colon tumor models [190]. However, the direct effect of vitamin $B_{12}$ deficiency on cancer onset, prognosis, and progression remains unresolved due to many inconsistent studies [191–196].

## 4. Discussion

In this review, we consolidate existing knowledge regarding the proteins involved in vitamin $B_{12}$ metabolism and explore their role in the cellular processes as well as the

impact of their dysfunction on overall metabolic integrity. Several proteins listed in Table 1, including transcobalamin, haptocorrin, Intrinsic Factor, cubilin, and amnionless, are already utilized in the diagnosis of vitamin $B_{12}$ deficiency. However, other proteins are primarily investigated at the gene level due to their intracellular localization or low detection levels in serum, limiting their use in routine diagnostics. Nonetheless, the levels of some of these proteins may harbor novel information concerning the risk of complications associated with vitamin $B_{12}$ deficiency.

**Table 1.** Proteins are involved in vitamin $B_{12}$ metabolism.

| Protein | Shortname | Gene | Type | Function | Pathology | Ref. |
|---|---|---|---|---|---|---|
| Haptocorrin, Transcobalamin I | HC, TC-I | *TCN1* | Glycoprotein | Binding vitamin $B_{12}$ in saliva and blood, transferring the vitamin to the stomach; Protection of vitamin $B_{12}$ from hydrolysis in the acidic pH of the stomach. | The inability of HC degradation and release of the vitamin from the vitamin $B_{12}$–HC complex (caused by deficiency of pancreatic proteases) may lead to vitamin $B_{12}$ malabsorption. | [15–20] |
| Intrinsic factor | IF | *GIF* or *CBLIF* | Glycoprotein | Binding vitamin $B_{12}$ in the duodenum. | The lack of IF in the condition of *H. pylori* infection or AIG leads to long-lasting vitamin $B_{12}$ deficiency due to the inability to deliver vitamin $B_{12}$ to the cells within the ileum. | [15,16,21] |
| Cubam receptor — Cubilin | CUBN | *CUBN* | Multiligand apical membrane receptor | Interaction with IF; Docking to transmembrane protein AMN; Forming with AMN a receptor specific for IF–vitamin $B_{12}$ internalization. | Damage of this cubam results in malabsorption of vitamin $B_{12}$ and the development of Imerslund–Gräsbeck syndrome (IGS), a rare autosomal recessive disorder that appears in childhood, characterized by megaloblastic anemia. | [32,33,36,37] |
| Cubam receptor — Type-1 transmembrane protein amnionless | AMN | *AMN* | | Clathrin-mediated internalization; Anchoring Cubilin; Forming with CUBN a receptor specific for IF–vitamin $B_{12}$ internalization. | | |
| Multidrug resistant protein 1 | MRP1, ABCC1 | *ABCC1* | ATP-binding cassette (ABC) transporters family | Effluxing vitamin $B_{12}$ from the intestinal epithelium to the blood circulation. | Mutations in the gene *ABCC1* were detected in some patients with vitamin $B_{12}$ malabsorption; however, it is an unlikely cause of Cbl deficiency in humans. | [46,47,52,54] |
| Transcobalamin | TC, TC-II | *TCN2* | β-globulin protein | Binding vitamin $B_{12}$ in the bloodstream; Facilitated distribution of vitamin $B_{12}$ into all cells in the body. | Mutations in the gene can lead to intracellular cobalamin depletion, causing a rare multisystemic disorder characterized by autosomal recessive inheritance. | [55,59,60,65–67] |
| Receptor for cluster of differentiation 320, Receptor for cobalamin-saturated transcobalamin | CD320, TCblR | *CD320* | Low-density Lipoprotein receptor protein family | Endocytosis of the TC–cobalamin complex. | Inconsistent studies: in 2010, Quadros et al. associated elevated MMA in five newborns with a mutation in *CD320*, while in 2022 Pangilinan et al. estimated that approximately 85% of infants with this mutation have unaffected cobalamin metabolism. | [68–70,72,73,80–82] |
| ATP-binding cassette sub-family D member 4 | ABCD4, CblJ protein | *ABCD4* | Exporter protein | Transport of free vitamin $B_{12}$ into the cytoplasm. | Mutations are related to disease groups cblJ and cblF. At the cellular level, both errors are marked with a decreased function of MMUT and MTR and an accumulation of free vitamin $B_{12}$ in the lysosomes. | [83,86–88,90,93] |
| Lysosomal cobalamin transport escort protein | LMBD1, CblF protein | *LMBRD1* | Adaptor protein, chaperone | Mediates the translocation of ABCD4 from ER to the lysosomes. | | |
| Methylmalonic aciduria and homocystinuria type C protein | MMACH, CblC protein | *MMACHC* | Chaperone, enzyme | Potentially receiving the Cbl cargo upon its release from the lysosomal compartment; Catalyzing the reductive decyanation and delkylation of cobalamin. | Mutations result in a rare genetic disorder referred to as methylmalonic aciduria and homocystinuria type C (cblC); deficiencies in both vitamin $B_{12}$-dependent enzymatic functions MTR and MMUT—accumulation of both MMA and Hcy in serum. | [94,96–98,102] |
| Methylmalonic aciduria and homocystinuria type D protein | MMADHC, CblD protein | *MMADHC* | Probably enzyme | Delivers Cbl-precursor to the production sites of MeCbl and AdoCb. | The cblD complementation group can be linked to isolated methylmalonic aciduria (cblD-MMA), isolated homocystinuria (cblD-HC), or a combination of both methylmalonic aciduria and homocystinuria (cblD-MMA/HC). | [105,107,108,111–113] |
| Methionine synthase | MTR, MS | *MTR* | Cytoplasmic enzyme | Vitamin $B_{12}$-dependent transfer of methyl group from 5-methyltetrahydrofolate to homocysteine with the production of tetrahydrofolate and methionine. | Missense mutation or deletion of three base pairs was identified in the cblG group of patients with cobalamin metabolism disorder and methylcobalamin deficiency cblE type, rare autosomal diseases associated with homocysteinemia, homocystinuria, and hypomethioninemia. | [81–84,86,87,115,123,124] |
| Methylmalonyl-CoA mutase | MMUT, MCM, MUT | *MMUT* | Mitochondrial enzyme | Vitamin $B_{12}$-dependent conversion methylmalonyl-CoA to succinyl-CoA. | Mutation leads to methylmalonic acidemia. | [88–90,92,128,131] |

In 2018, Tseng et al. established that mice models demonstrated that a loss of single allele *Lmbd1* would result in ventricular hypertrophy, which was accompanied by enhanced myocardial glucose uptake [197]. Moreover, a microarray screening study revealed a 25% reduction in LMBD1 mRNA levels in the septa of 13 heart transplant patients with dilated cardiomyopathy compared to non-failing hearts [198]. This clinical observation, coupled with the findings from mice studies, suggests that diminished expression of LMBD1 protein may play a role in the development of cardiomyopathy. Thus, the single nucleotide polymorphism sites associated with decreased expression of the human *LMBRD1* gene evaluation may not only indicate the cause of vitamin $B_{12}$ deficiency but also prognose a risk of onset of cardiovascular diseases.

Interestingly, the diminished expression of other proteins involved in vitamin $B_{12}$- has been noted in the brains of multiple sclerosis patients, highlighting the role of this protein in proper central nervous system function [199]. It was accompanied by worsening the disease by both CD320 genetic deletion and vitamin $B_{12}$ deficiency [199]. These findings highlight a plausible connection between vitamin $B_{12}$ deficiency and the progression of pathology in patients with multiple sclerosis. One may conclude that vitamin $B_{12}$ deficiency caused by CD320 disruption might be linked with an increased risk of neurodegenerative diseases; thus, its evaluation might be an interesting prognostic parameter.

Another protein linked with vitamin $B_{12}$ metabolism that exhibits multifunctional properties is MRP1. MRP1 transports a wide range of therapeutic agents as well as various physiological substrates and may contribute to drug resistance development in several cancers, including lung, breast, and prostate cancers, as well as childhood neuroblastoma [200]. MRP1's role as a glutathione transporter creates a unique vulnerability in cancer cells with high MRP1 expression, providing a potential therapeutic opportunity for targeting cancer. Direct pharmacological inhibition of MRP1 shows promise and is extensively tested in preclinical and clinical studies [201–203]. However, non-selective MRP1 inhibition could potentially disrupt vitamin $B_{12}$ metabolism and lead to its deficiency. Therefore, there is an emerging need to investigate the effects of MRP-1 inhibition on vitamin $B_{12}$ metabolism during therapy.

Interestingly, it has been noted that the utilization of the common drug metformin in diabetic patients is linked to potential malabsorption and deficiency of vitamin $B_{12}$ [204,205]. Numerous observational studies and meta-analyses have underscored a significant correlation between metformin usage and vitamin $B_{12}$ deficiency [206]. Patients undergoing metformin therapy display reduced absorption of $B_{12}$, leading to decreased levels of serum total vitamin $B_{12}$ and holoTC ("active vitamin $B_{12}$"). This phenomenon is attributed to calcium-dependent antagonism in the ileal membrane, which may be mitigated through calcium supplementation [207]. Given these findings, it is strongly advised that individuals using metformin undergo regular monitoring of their vitamin $B_{12}$ levels. This precaution is crucial as prolonged metformin usage may deplete hepatic vitamin $B_{12}$ reserves [208].

## 5. Conclusions

Despite the initiation of studies on vitamin $B_{12}$ as early as in the 1948s, our understanding of its biochemical alterations remains incomplete. Over the past decade, there has been a notable surge in research attention directed toward vitamin $B_{12}$ biochemical, physiological, and clinical facets. Surprisingly, some recent studies suggested that vitamin $B_{12}$ may affect gene expression, cellular plasticity, and tissue repair [178,209]. However, the specific molecules and cellular changes mediated by these alterations are still not fully elucidated.

Besides the fact that vitamin $B_{12}$ deficiency leads to the presence of serious clinical manifestations, numerous studies have highlighted the correlation between low vitamin $B_{12}$ levels and the increased risk of civilization diseases. Importantly, some of the proteins involved in vitamin $B_{12}$ metabolism may act as moonlighting proteins and their pharmacological modification already used in the treatment of other clinical stages may implicate also proper vitamin $B_{12}$ metabolism.

Hence, there is a pressing need for more basic science studies to unravel the vitamin $B_{12}$ metabolism complexity that may lower the risk of vitamin $B_{12}$ deficiency in clinical studies as well as potentially identify novel diagnostic parameters that may contribute to evaluating the risk of vitamin $B_{12}$ deficiency consequences.

**Author Contributions:** Conceptualization, P.M., F.K. and M.T.; writing—original draft preparation, P.M., F.K., D.C. and M.T.; writing—review and editing, M.T. and R.T.S.; supervision, M.T. and R.T.S. All authors have read and agreed to the published version of the manuscript.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Folkers, K. History of Vitamin B12: Pernicious Anemia to Crystalline Cyanocobalamin. In *Vitamin B12*; John Wiley & Sons: New York, NY, USA, 1982; Volume I.
2. Randaccio, L.; Geremia, S.; Demitri, N.; Wuerges, J. Vitamin B12: Unique Metalorganic Compounds and the Most Complex Vitamins. *Molecules* **2010**, *15*, 3228–3259. [CrossRef]
3. Obeid, R.; Fedosov, S.N.; Nexo, E. Cobalamin Coenzyme Forms Are Not Likely to Be Superior to Cyano- and Hydroxyl-cobalamin in Prevention or Treatment of Cobalamin Deficiency. *Mol. Nutr. Food Res.* **2015**, *59*, 1364–1372. [CrossRef]
4. Kurmaev, E.Z.; Moewes, A.; Ouyang, L.; Randaccio, L.; Rulis, P.; Ching, W.Y.; Bach, M.; Neumann, M. The Electronic Structure and Chemical Bonding of Vitamin B$_{12}$. *Europhys. Lett.* **2003**, *62*, 582–587. [CrossRef]
5. Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and Its Panel on Folate, Other B Vitamins, and Choline. *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline*; National Academies Press: Washington, DC, USA, 1998; ISBN 978-0-309-06554-2.
6. Herrmann, W.; Obeid, R. Cobalamin deficiency. *Subcell. Biochem.* **2012**, *56*, 301–322. [CrossRef]
7. Santos, F.; Vera, J.L.; Lamosa, P.; de Valdez, G.F.; de Vos, W.M.; Santos, H.; Sesma, F.; Hugenholtz, J. Pseudovitamin Is the Corrinoid Produced by *Lactobacillus reuteri* CRL1098 under Anaerobic Conditions. *FEBS Lett.* **2007**, *581*, 4865–4870. [CrossRef]
8. Latner, A.L.; Raine, L. Effect of Analogues on the Uptake of Vitamin B12 by the Intact Rat. *Nature* **1957**, *180*, 1197–1198. [CrossRef]
9. Bito, T.; Bito, M.; Hirooka, T.; Okamoto, N.; Harada, N.; Yamaji, R.; Nakano, Y.; Inui, H.; Watanabe, F. Biological Activity of Pseudovitamin B12 on Cobalamin-Dependent Methylmalonyl-CoA Mutase and Methionine Synthase in Mammalian Cultured COS-7 Cells. *Molecules* **2020**, *25*, 3268. [CrossRef]
10. Watanabe, F. Vitamin B12 Sources and Bioavailability. *Exp. Biol. Med.* **2007**, *232*, 1266–1274. [CrossRef]
11. Green, R.; Allen, L.H.; Bjørke-Monsen, A.-L.; Brito, A.; Guéant, J.-L.; Miller, J.W.; Molloy, A.M.; Nexo, E.; Stabler, S.; Toh, B.-H.; et al. Vitamin B12 Deficiency. *Nat. Rev. Dis. Primers* **2017**, *3*, 17040. [CrossRef]
12. Gherasim, C.; Lofgren, M.; Banerjee, R. Navigating the B12 Road: Assimilation, Delivery, and Disorders of Cobalamin. *J. Biol. Chem.* **2013**, *288*, 13186–13193. [CrossRef]
13. O'Leary, F.; Samman, S. Vitamin B$_{12}$ in Health and Disease. *Nutrients* **2010**, *2*, 299–316. [CrossRef]
14. Kozyraki, R.; Cases, O. Vitamin B12 Absorption: Mammalian Physiology and Acquired and Inherited Disorders. *Biochimie* **2013**, *95*, 1002–1007. [CrossRef]
15. Wuerges, J.; Geremia, S.; Randaccio, L. Structural Study on Ligand Specificity of Human Vitamin B12 Transporters. *Biochem. J.* **2007**, *403*, 431–440. [CrossRef]
16. Mathews, F.S.; Gordon, M.M.; Chen, Z.; Rajashankar, K.R.; Ealick, S.E.; Alpers, D.H.; Sukumar, N. Crystal Structure of Human Intrinsic Factor: Cobalamin Complex at 2.6-Å Resolution. *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 17311–17316. [CrossRef]
17. Alpers, D.H.; Russell-Jones, G. Gastric Intrinsic Factor: The Gastric and Small Intestinal Stages of Cobalamin Absorption. A Personal Journey. *Biochimie* **2013**, *95*, 989–994. [CrossRef]
18. Hewitt, J.E.; Gordon, M.M.; Taggart, R.T.; Mohandas, T.K.; Alpers, D.H. Human Gastric Intrinsic Factor: Characterization of CDNA and Genomic Clones and Localization to Human Chromosome 11. *Genomics* **1991**, *10*, 432–440. [CrossRef]
19. Yang, S.Y.; Coleman, P.S.; Dupont, B. The Biochemical and Genetic Basis for the Microheterogeneity of Human R-Type Vitamin B12 Binding Proteins. *Blood* **1982**, *59*, 747–755. [CrossRef]
20. Furger, E.; Frei, D.C.; Schibli, R.; Fischer, E.; Prota, A.E. Structural Basis for Universal Corrinoid Recognition by the Cobalamin Transport Protein Haptocorrin. *J. Biol. Chem.* **2013**, *288*, 25466–25476. [CrossRef]
21. Nielsen, M.J.; Rasmussen, M.R.; Andersen, C.B.F.; Nexø, E.; Moestrup, S.K. Vitamin B12 Transport from Food to the Body's Cells—A Sophisticated, Multistep Pathway. *Nat. Rev. Gastroenterol. Hepatol.* **2012**, *9*, 345–354. [CrossRef]
22. Henderson, J.T.; Warwick, R.R.G.; Simpson, J.D.; Shearman, D.J.C. Does Malabsorption of Vitamin B12 Occur in Chronic Pancreatitis? *Lancet* **1972**, *300*, 241–243. [CrossRef]
23. Guéant, J.-L.; Champigneulle, B.; Gaucher, P.; Nicolas, J.-P. Malabsorption of Vitamin B12 in Pancreatic Insufficiency of the Adult and of the Child. *Pancreas* **1990**, *5*, 559–567. [CrossRef] [PubMed]
24. Forsmark, C.E. Diagnosis and Management of Exocrine Pancreatic Insufficiency. *Curr. Treat. Options Gastroenterol.* **2018**, *16*, 306–315. [CrossRef] [PubMed]
25. Hygum, K.; Lildballe, D.L.; Greibe, E.H.; Morkbak, A.L.; Poulsen, S.S.; Sorensen, B.S.; Petersen, T.E.; Nexo, E. Mouse Transcobalamin Has Features Resembling Both Human Transcobalamin and Haptocorrin. *PLoS ONE* **2011**, *6*, e20638. [CrossRef] [PubMed]
26. Fedosov, S.N.; Fedosova, N.U.; Berglund, L.; Moestrup, S.K.; Nexø, E.; Petersen, T.E. Assembly of the Intrinsic Factor Domains and Oligomerization of the Protein in the Presence of Cobalamin. *Biochemistry* **2004**, *43*, 15095–15102. [CrossRef] [PubMed]
27. Fedosov, S.N.; Fedosova, N.U.; Kräutler, B.; Nexø, E.; Petersen, T.E. Mechanisms of Discrimination between Cobalamins and Their Natural Analogues during Their Binding to the Specific B$_{12}$-Transporting Proteins. *Biochemistry* **2007**, *46*, 6446–6458. [CrossRef] [PubMed]
28. Ayesh, M.H.; Jadalah, K.; Al Awadi, E.; Alawneh, K.; Khassawneh, B. Association between Vitamin B12 Level and Anti-Parietal Cells and Anti-Intrinsic Factor Antibodies among Adult Jordanian Patients with Helicobacter Pylori Infection. *Braz. J. Infect. Dis.* **2013**, *17*, 629–632. [CrossRef]
29. Lenti, M.V.; Rugge, M.; Lahner, E.; Miceli, E.; Toh, B.-H.; Genta, R.M.; De Block, C.; Hershko, C.; Di Sabatino, A. Autoimmune Gastritis. *Nat. Rev. Dis. Primers* **2020**, *6*, 56. [CrossRef] [PubMed]

30. Htut, T.W.; Thein, K.Z.; Oo, T.H. Pernicious Anemia: Pathophysiology and Diagnostic Difficulties. *J. Evid. Based Med.* **2021**, *14*, 161–169. [CrossRef]
31. Qudsiya, Z.; De Jesus, O. *Subacute Combined Degeneration of the Spinal Cord*; StatPearls Publishing: Treasure Island, FL, USA, 2022.
32. Larsen, C.; Etzerodt, A.; Madsen, M.; Skjødt, K.; Moestrup, S.K.; Andersen, C.B.F. Structural Assembly of the Megadalton-Sized Receptor for Intestinal Vitamin B12 Uptake and Kidney Protein Reabsorption. *Nat. Commun.* **2018**, *9*, 5204. [CrossRef] [PubMed]
33. Pedersen, G.A.; Chakraborty, S.; Steinhauser, A.L.; Traub, L.M.; Madsen, M. AMN Directs Endocytosis of the Intrinsic Factor-Vitamin B12 Receptor Cubam by Engaging ARH or Dab2. *Traffic* **2010**, *11*, 706–720. [CrossRef]
34. Strope, S.; Rivi, R.; Metzger, T.; Manova, K.; Lacy, E. Mouse Amnionless, Which Is Required for Primitive Streak Assembly, Mediates Cell-Surface Localization and Endocytic Function of Cubilin on Visceral Endoderm and Kidney Proximal Tubules. *Development* **2004**, *131*, 4787–4795. [CrossRef]
35. Perea-Gomez, A.; Cases, O.; Lelièvre, V.; Pulina, M.V.; Collignon, J.; Hadjantonakis, A.-K.; Kozyraki, R. Loss of Cubilin, the Intrinsic Factor-Vitamin B12 Receptor, Impairs Visceral Endoderm Endocytosis and Endodermal Patterning in the Mouse. *Sci. Rep.* **2019**, *9*, 10168. [CrossRef] [PubMed]
36. Christensen, E.I.; Verroust, P.J.; Nielsen, R. Receptor-Mediated Endocytosis in Renal Proximal Tubule. *Pflügers Arch. Eur. J. Physiol.* **2009**, *458*, 1039–1048. [CrossRef] [PubMed]
37. Andersen, C.B.F.; Madsen, M.; Storm, T.; Moestrup, S.K.; Andersen, G.R. Structural Basis for Receptor Recognition of Vitamin-B12–Intrinsic Factor Complexes. *Nature* **2010**, *464*, 445–448. [CrossRef] [PubMed]
38. Amsellem, S.; Gburek, J.; Hamard, G.; Nielsen, R.; Willnow, T.E.; Devuyst, O.; Nexo, E.; Verroust, P.J.; Christensen, E.I.; Kozyraki, R. Cubilin Is Essential for Albumin Reabsorption in the Renal Proximal Tubule. *J. Am. Soc. Nephrol.* **2010**, *21*, 1859–1867. [CrossRef] [PubMed]
39. Fyfe, J.C.; Madsen, M.; Højrup, P.; Christensen, E.I.; Tanner, S.M.; de la Chapelle, A.; He, Q.; Moestrup, S.K. The Functional Cobalamin (Vitamin B12)–Intrinsic Factor Receptor Is a Novel Complex of Cubilin and Amnionless. *Blood* **2004**, *103*, 1573–1579. [CrossRef]
40. Jensen, L.L.; Andersen, R.K.; Hager, H.; Madsen, M. Lack of Megalin Expression in Adult Human Terminal Ileum Suggests Megalin-Independent Cubilin/Amnionless Activity during Vitamin $B_{12}$ Absorption. *Physiol. Rep.* **2014**, *2*, e12086. [CrossRef] [PubMed]
41. Gräsbeck, R. Imerslund-Gräsbeck Syndrome (Selective Vitamin B12 Malabsorption with Proteinuria). *Orphanet J. Rare Dis.* **2006**, *1*, 17. [CrossRef]
42. Kingma, S.D.K.; Neven, J.; Bael, A.; Meuwissen, M.E.C.; van den Akker, M. Imerslund-Gräsbeck Syndrome: A Comprehensive Review of Reported Cases. *Orphanet J. Rare Dis.* **2023**, *18*, 291. [CrossRef]
43. Storm, T.; Zeitz, C.; Cases, O.; Amsellem, S.; Verroust, P.J.; Madsen, M.; Benoist, J.-F.; Passemard, S.; Lebon, S.; Jønsson, I.M.; et al. Detailed Investigations of Proximal Tubular Function in Imerslund-Gräsbeck Syndrome. *BMC Med. Genet.* **2013**, *14*, 111. [CrossRef]
44. Ercan, Z.; Demir, M.E.; Ulas, T.; Ingec, M.; Horoz, M. A Long-Term Follow-up of an Imerslund-Grasbeck Syndrome Patient with Proteinuria. *Nefrologia* **2013**, *33*, 147–148. [CrossRef] [PubMed]
45. Pannérec, A.; Migliavacca, E.; De Castro, A.; Michaud, J.; Karaz, S.; Goulet, L.; Rezzi, S.; Ng, T.P.; Bosco, N.; Larbi, A.; et al. Vitamin B12 Deficiency and Impaired Expression of Amnionless during Aging. *J. Cachexia Sarcopenia Muscle* **2018**, *9*, 41–52. [CrossRef]
46. Cole, S.P.C. Multidrug Resistance Protein 1 (MRP1, ABCC1), a "Multitasking" ATP-Binding Cassette (ABC) Transporter. *J. Biol. Chem.* **2014**, *289*, 30880–30888. [CrossRef] [PubMed]
47. Cole, S.P.C.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.; Almquist, K.C.; Stewart, A.J.; Kurz, E.U.; Duncan, A.M.V.; Deeley, R.G. Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line. *Science* **1992**, *258*, 1650–1654. [CrossRef] [PubMed]
48. Bakos, É.; Homolya, L. Portrait of Multifaceted Transporter, the Multidrug Resistance-Associated Protein 1 (MRP1/ABCC1). *Pflugers Arch. Eur. J. Physiol.* **2007**, *453*, 621–641. [CrossRef]
49. Flens, M.J.; Zaman, G.J.; van der Valk, P.; Izquierdo, M.A.; Schroeijers, A.B.; Scheffer, G.L.; van der Groep, P.; de Haas, M.; Meijer, C.J.; Scheper, R.J. Tissue Distribution of the Multidrug Resistance Protein. *Am. J. Pathol.* **1996**, *148*, 1237–1247.
50. Peng, K.-C.; Cluzeaud, F.; Bens, M.; Duong Van Huyen, J.-P.; Wioland, M.A.; Lacave, R.; Vandewalle, A. Tissue and Cell Distribution of the Multidrug Resistance-Associated Protein (MRP) in Mouse Intestine and Kidney. *J. Histochem. Cytochem.* **1999**, *47*, 757–767. [CrossRef]
51. Rajagopal, A.; Simon, S.M. Subcellular Localization and Activity of Multidrug Resistance Proteins. *Mol. Biol. Cell* **2003**, *14*, 3389–3399. [CrossRef]
52. Beedholm-Ebsen, R.; van de Wetering, K.; Hardlei, T.; Nexø, E.; Borst, P.; Moestrup, S.K. Identification of Multidrug Resistance Protein 1 (MRP1/ABCC1) as a Molecular Gate for Cellular Export of Cobalamin. *Blood* **2010**, *115*, 1632–1639. [CrossRef]
53. Seetharam, B.; Yammani, R.R. Cobalamin Transport Proteins and Their Cell-Surface Receptors. *Expert Rev. Mol. Med.* **2003**, *5*, 1–18. [CrossRef]
54. Shah, N.P.; Beech, C.M.; Sturm, A.C.; Tanner, S.M. Investigation of the ABC Transporter MRP1 in Selected Patients with Presumed Defects in Vitamin B12 Absorption. *Blood* **2011**, *117*, 4397–4398. [CrossRef] [PubMed]

55. Quadros, E.V.; Rothenberg, S.P.; Pan, Y.C.; Stein, S. Purification and Molecular Characterization of Human Transcobalamin II. *J. Biol. Chem.* **1986**, *261*, 15455–15460. [CrossRef] [PubMed]

56. Quadros, E.V.; Rothenberg, S.P.; Jaffe, E.A. Endothelial Cells from Human Umbilical Vein Secrete Functional Transcobalamin II. *Am. J. Physiol. Cell Physiol.* **1989**, *256*, C296–C303. [CrossRef] [PubMed]

57. Quadros, E.V.; Regec, A.L.; Khan, K.M.F.; Quadros, E.; Rothenberg, S.P. Transcobalamin II Synthesized in the Intestinal Villi Facilitates Transfer of Cobalamin to the Portal Blood. *Am. J. Physiol. Gastrointest. Liver Physiol.* **1999**, *277*, G161–G166. [CrossRef] [PubMed]

58. Li, N.; Seetharam, S.; Seetharam, B. Genomic Structure of Human Transcobalamin II: Comparison to Human Intrinsic Factor and Transcobalamin I. *Biochem. Biophys. Res. Commun.* **1995**, *208*, 756–764. [CrossRef] [PubMed]

59. Wuerges, J.; Garau, G.; Geremia, S.; Fedosov, S.N.; Petersen, T.E.; Randaccio, L. Structural Basis for Mammalian Vitamin B$_{12}$ Transport by Transcobalamin. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 4386–4391. [CrossRef] [PubMed]

60. Obeid, R.; Morkbak, A.L.; Munz, W.; Nexo, E.; Herrmann, W. The Cobalamin-Binding Proteins Transcobalamin and Haptocorrin in Maternal and Cord Blood Sera at Birth. *Clin. Chem.* **2006**, *52*, 263–269. [CrossRef] [PubMed]

61. Thorpe, S.J.; Rigsby, P.; Roberts, G.; Lee, A.; Hamilton, M.; Craig, D. An International Standard for Holotranscobalamin (HoloTC): International Collaborative Study to Assign a HoloTC Value to the International Standard for Vitamin B12 and Serum Folate. *Clin. Chem. Lab. Med. CCLM* **2016**, *54*, 1467–1472. [CrossRef] [PubMed]

62. Knoepfel, C.; Michel Blanco, M.; Nydegger, U.; Risch, L.; Renz, H.; Risch, M. Failure of the Holotranscobalamin Assay in Vitamin B12-Deficient Patients. *J. Lab. Med.* **2018**, *42*, 141–147. [CrossRef]

63. Golding, P.H. Experimental Vitamin B12 Deficiency in a Human Subject: A Longitudinal Investigation of the Performance of the Holotranscobalamin (HoloTC, Active-B12) Immunoassay. *SpringerPlus* **2016**, *5*, 184. [CrossRef]

64. Golding, P.H. Holotranscobalamin (HoloTC, Active-B12) and Herbert's Model for the Development of Vitamin B12 Deficiency: A Review and Alternative Hypothesis. *SpringerPlus* **2016**, *5*, 668. [CrossRef] [PubMed]

65. Trakadis, Y.J.; Alfares, A.; Bodamer, O.A.; Buyukavci, M.; Christodoulou, J.; Connor, P.; Glamuzina, E.; Gonzalez-Fernandez, F.; Bibi, H.; Echenne, B.; et al. Update on Transcobalamin Deficiency: Clinical Presentation, Treatment and Outcome. *J. Inherit. Metab. Dis.* **2014**, *37*, 461–473. [CrossRef]

66. Nissen, P.H.; Nordwall, M.; Hoffmann-Lücke, E.; Sorensen, B.S.; Nexo, E. Transcobalamin Deficiency Caused by Compound Heterozygosity for Two Novel Mutations in the *TCN2* Gene: A Study of Two Affected Siblings, Their Brother, and Their Parents. *J. Inherit. Metab. Dis.* **2010**, *33*, 269–274. [CrossRef] [PubMed]

67. Oshi, M.A.M.; Alfaifi, J.; Alqahtani, Y.A.M.; Aljabri, M.F.; Kamal, N.M.; Althopaity, J.; Althobaiti, K.A.; Almalki, A.M.; Abosabie, S.A.S.; Abosabie, S.A.; et al. Progressive Myoclonic Ataxia and Developmental/Epileptic Encephalopathy Associated with a Novel Homozygous Mutation in *TCN2* Gene. *Mol. Genet. Genom. Med.* **2024**, *12*, e2282. [CrossRef]

68. Quadros, E.V. Advances in the Understanding of Cobalamin Assimilation and Metabolism. *Br. J. Haematol.* **2010**, *148*, 195–204. [CrossRef] [PubMed]

69. Cho, W.-J.; Choi, J.-S.; Park, C.-H.; Yoon, S.-O.; Jeoung, D.-I.; Kim, Y.-M.; Choe, J.-S. Expression of CD320 in Human B Cells in Addition to Follicular Dendritic Cells. *BMB Rep.* **2008**, *41*, 863–867. [CrossRef] [PubMed]

70. Jiang, W.; Nakayama, Y.; Sequeira, J.M.; Quadros, E.V. Mapping the Functional Domains of TCblR/*CD320*, the Receptor for Cellular Uptake of Transcobalamin-bound Cobalamin. *FASEB J.* **2013**, *27*, 2988–2994. [CrossRef] [PubMed]

71. Arendt, J.F.B.; Quadros, E.V.; Nexo, E. Soluble Transcobalamin Receptor, SCD320, Is Present in Human Serum and Relates to Serum Cobalamin—Establishment and Validation of an ELISA. *Clin. Chem. Lab. Med.* **2012**, *50*, 515–519. [CrossRef]

72. Youngdahl-Turner, P.; Mellman, I.S.; Allen, R.H.; Rosenberg, L.E. Protein Mediated Vitamin Uptake. *Exp. Cell. Res.* **1979**, *118*, 127–134. [CrossRef]

73. Alam, A.; Woo, J.-S.; Schmitz, J.; Prinz, B.; Root, K.; Chen, F.; Bloch, J.S.; Zenobi, R.; Locher, K.P. Structural Basis of Transcobalamin Recognition by Human CD320 Receptor. *Nat. Commun.* **2016**, *7*, 12100. [CrossRef]

74. Gick, G.G.; Arora, K.; Sequeira, J.M.; Nakayama, Y.; Lai, S.-C.; Quadros, E.V. Cellular Uptake of Vitamin B12: Role and Fate of TCblR/CD320, the Transcobalamin Receptor. *Exp. Cell Res.* **2020**, *396*, 112256. [CrossRef]

75. Quadros, E.V.; Jacobsen, D.W. The Dynamics of Cobalamin Utilization in L-1210 Mouse Leukemia Cells: A Model of Cellular Cobalamin Metabolism. *Biochim. Biophys. Acta BBA Gen. Subj.* **1995**, *1244*, 395–403. [CrossRef]

76. Bernard, D.J.; Pangilinan, F.J.; Cheng, J.; Molloy, A.M.; Brody, L.C. Mice Lacking the Transcobalamin-Vitamin B12 Receptor, CD320, Suffer from Anemia and Reproductive Deficits When Fed Vitamin B12-Deficient Diet. *Hum. Mol. Genet.* **2018**, *27*, 3627–3640. [CrossRef]

77. Westerman, D.; Evans, D.; Metz, J. Neutrophil Hypersegmentation in Iron Deficiency Anaemia: A Case-Control Study. *Br. J. Haematol.* **1999**, *107*, 512–515. [CrossRef]

78. Arora, K.; Sequeira, J.M.; Hernández, A.I.; Alarcon, J.M.; Quadros, E.V. Behavioral Alterations Are Associated with Vitamin B12 Deficiency in the Transcobalamin Receptor/CD320 KO Mouse. *PLoS ONE* **2017**, *12*, e0177156. [CrossRef]

79. Fernàndez-Roig, S.; Lai, S.-C.; Murphy, M.M.; Fernandez-Ballart, J.; Quadros, E.V. Vitamin B12 Deficiency in the Brain Leads to DNA Hypomethylation in the TCblR/CD320 Knockout Mouse. *Nutr. Metab.* **2012**, *9*, 41. [CrossRef]

80. Kurnat-Thoma, E.L.; Pangilinan, F.; Matteini, A.M.; Wong, B.; Pepper, G.A.; Stabler, S.P.; Guralnik, J.M.; Brody, L.C. Association of Transcobalamin II (*TCN2*) and Transcobalamin II-Receptor (*TCblR*) Genetic Variations with Cobalamin Deficiency Parameters in Elderly Women. *Biol. Res. Nurs.* **2015**, *17*, 444–454. [CrossRef]

81. Quadros, E.V.; Lai, S.-C.; Nakayama, Y.; Sequeira, J.M.; Hannibal, L.; Wang, S.; Jacobsen, D.W.; Fedosov, S.; Wright, E.; Gallagher, R.C.; et al. Positive Newborn Screen for Methylmalonic Aciduria Identifies the First Mutation in TCblR/*CD320*, the Gene for Cellular Uptake of Transcobalamin-Bound Vitamin B$_{12}$. *Hum. Mutat.* **2010**, *31*, 924–929. [CrossRef]

82. Pangilinan, F.; Watkins, D.; Bernard, D.; Chen, Y.; Dong, N.; Wu, Q.; Ozel-Abaan, H.; Kaur, M.; Caggana, M.; Morrissey, M.; et al. Probing the Functional Consequence and Clinical Relevance of *CD320* p.E88del, a Variant in the Transcobalamin Receptor Gene. *Am. J. Med. Genet. Part A* **2022**, *188*, 1124–1141. [CrossRef]

83. Coelho, D.; Kim, J.C.; Miousse, I.R.; Fung, S.; du Moulin, M.; Buers, I.; Suormala, T.; Burda, P.; Frapolli, M.; Stucki, M.; et al. Mutations in ABCD4 Cause a New Inborn Error of Vitamin B12 Metabolism. *Nat. Genet.* **2012**, *44*, 1152–1155. [CrossRef]

84. Seeger, M.A.; van Veen, H.W. Molecular Basis of Multidrug Transport by ABC Transporters. *Biochim. Biophys. Acta BBA Proteins Proteom.* **2009**, *1794*, 725–737. [CrossRef]

85. Xu, D.; Feng, Z.; Hou, W.-T.; Jiang, Y.-L.; Wang, L.; Sun, L.; Zhou, C.-Z.; Chen, Y. Cryo-EM Structure of Human Lysosomal Cobalamin Exporter ABCD4. *Cell Res.* **2019**, *29*, 1039–1041. [CrossRef]

86. Deme, J.C.; Hancock, M.A.; Xia, X.; Shintre, C.A.; Plesa, M.; Kim, J.C.; Carpenter, E.P.; Rosenblatt, D.S.; Coulton, J.W. Purification and Interaction Analyses of Two Human Lysosomal Vitamin B$_{12}$ Transporters: LMBD1 and ABCD4. *Mol. Membr. Biol.* **2014**, *31*, 250–261. [CrossRef]

87. Rutsch, F.; Gailus, S.; Miousse, I.R.; Suormala, T.; Sagné, C.; Toliat, M.R.; Nürnberg, G.; Wittkampf, T.; Buers, I.; Sharifi, A.; et al. Identification of a Putative Lysosomal Cobalamin Exporter Altered in the CblF Defect of Vitamin B12 Metabolism. *Nat. Genet.* **2009**, *41*, 234–239. [CrossRef]

88. Kawaguchi, K.; Okamoto, T.; Morita, M.; Imanaka, T. Translocation of the ABC Transporter ABCD4 from the Endoplasmic Reticulum to Lysosomes Requires the Escort Protein LMBD1. *Sci. Rep.* **2016**, *6*, 30183. [CrossRef]

89. Watkins, D.; Rosenblatt, D.S. Lessons in Biology from Patients with Inherited Disorders of Vitamin B12 and Folate Metabolism. *Biochimie* **2016**, *126*, 3–5. [CrossRef]

90. Sloan, J.L.; Carrillo, N.; Adams, D.; Venditti, C.P. Disorders of Intracellular Cobalamin Metabolism. In *GeneReviews*; Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Gripp, K.W., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 2021.

91. Kim, J.C.; Lee, N.-C.; Hwu, P.W.-L.; Chien, Y.-H.; Fahiminiya, S.; Majewski, J.; Watkins, D.; Rosenblatt, D.S. Late Onset of Symptoms in an Atypical Patient with the CblJ Inborn Error of Vitamin B12 Metabolism: Diagnosis and Novel Mutation Revealed by Exome Sequencing. *Mol. Genet. Metab.* **2012**, *107*, 664–668. [CrossRef]

92. Miousse, I.R.; Watkins, D.; Rosenblatt, D.S. Novel Splice Site Mutations and a Large Deletion in Three Patients with the CblF Inborn Error of Vitamin B12 Metabolism. *Mol. Genet. Metab.* **2011**, *102*, 505–507. [CrossRef]

93. Alfadhel, M.; Lillquist, Y.P.; Davis, C.; Junker, A.K.; Stockler-Ipsiroglu, S. Eighteen-year Follow-up of a Patient with Cobalamin F Disease (CblF): Report and Review. *Am. J. Med. Genet. Part A* **2011**, *155*, 2571–2577. [CrossRef]

94. Lerner-Ellis, J.P.; Anastasio, N.; Liu, J.; Coelho, D.; Suormala, T.; Stucki, M.; Loewy, A.D.; Gurd, S.; Grundberg, E.; Morel, C.F.; et al. Spectrum of Mutations in *MMACHC*, Allelic Expression, and Evidence for Genotype-Phenotype Correlations. *Hum. Mutat.* **2009**, *30*, 1072–1081. [CrossRef]

95. Wang, C.; Li, D.; Cai, F.; Zhang, X.; Xu, X.; Liu, X.; Zhang, C.; Wang, D.; Liu, X.; Lin, S.; et al. Mutation Spectrum of MMACHC in Chinese Pediatric Patients with Cobalamin C Disease: A Case Series and Literature Review. *Eur. J. Med. Genet.* **2019**, *62*, 103713. [CrossRef] [PubMed]

96. Lerner-Ellis, J.P.; Tirone, J.C.; Pawelek, P.D.; Doré, C.; Atkinson, J.L.; Watkins, D.; Morel, C.F.; Fujiwara, T.M.; Moras, E.; Hosack, A.R.; et al. Identification of the Gene Responsible for Methylmalonic Aciduria and Homocystinuria, CblC Type. *Nat. Genet.* **2006**, *38*, 93–100. [CrossRef] [PubMed]

97. Guéant, J.-L.; Chéry, C.; Oussalah, A.; Nadaf, J.; Coelho, D.; Josse, T.; Flayac, J.; Robert, A.; Koscinski, I.; Gastin, I.; et al. A PRDX1 Mutant Allele Causes a MMACHC Secondary Epimutation in CblC Patients. *Nat. Commun.* **2018**, *9*, 67. [CrossRef] [PubMed]

98. Kim, J.; Gherasim, C.; Banerjee, R. Decyanation of Vitamin B12 by a Trafficking Chaperone. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 14551–14554. [CrossRef] [PubMed]

99. Pezacka, E.; Green, R.; Jacobsen, D.W. Glutathionylcobalamin as an Intermediate in the Formation of Cobalamin Coenzymes. *Biochem. Biophys. Res. Commun.* **1990**, *169*, 443–450. [CrossRef]

100. Mellman, I.; Willard, H.F.; Youngdahl-Turner, P.; Rosenberg, L.E. Cobalamin Coenzyme Synthesis in Normal and Mutant Human Fibroblasts. Evidence for a Processing Enzyme Activity Deficient in CblC Cells. *J. Biol. Chem.* **1979**, *254*, 11847–11853. [CrossRef] [PubMed]

101. Bassila, C.; Ghemrawi, R.; Flayac, J.; Froese, D.S.; Baumgartner, M.R.; Guéant, J.-L.; Coelho, D. Methionine Synthase and Methionine Synthase Reductase Interact with MMACHC and with MMADHC. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* **2017**, *1863*, 103–112. [CrossRef]

102. Kalantari, S.; Brezzi, B.; Bracciamà, V.; Barreca, A.; Nozza, P.; Vaisitti, T.; Amoroso, A.; Deaglio, S.; Manganaro, M.; Porta, F.; et al. Adult-Onset CblC Deficiency: A Challenging Diagnosis Involving Different Adult Clinical Specialists. *Orphanet J. Rare Dis.* **2022**, *17*, 33. [CrossRef]

103. Sorin, M.; Watkins, D.; Gilfix, B.M.; Rosenblatt, D.S. Methionine Dependence in Tumor Cells: The Potential Role of Cobalamin and MMACHC. *Mol. Genet. Metab.* **2021**, *132*, 155–161. [CrossRef]

104. Bauer, W.G.; Watkins, D.; Zacharias, C.; Gilfix, B.M.; Rosenblatt, D.S. Growth Requirement for Methionine in Human Melanoma-Derived Cell Lines with Different Levels of MMACHC Expression and Methylation. *Mol. Genet. Metab.* **2024**, *141*, 108111. [CrossRef]

105. Coelho, D.; Suormala, T.; Stucki, M.; Lerner-Ellis, J.P.; Rosenblatt, D.S.; Newbold, R.F.; Baumgartner, M.R.; Fowler, B. Gene Identification for the CblD Defect of Vitamin B$_{12}$ Metabolism. *N. Engl. J. Med.* **2008**, *358*, 1454–1464. [CrossRef]

106. Li, Z.; Mascarenhas, R.; Twahir, U.T.; Kallon, A.; Deb, A.; Yaw, M.; Penner-Hahn, J.; Koutmos, M.; Warncke, K.; Banerjee, R. An Interprotein Co–S Coordination Complex in the B$_{12}$-Trafficking Pathway. *J. Am. Chem. Soc.* **2020**, *142*, 16334–16345. [CrossRef]

107. Pupavac, M.; Garcia, M.A.M.; Rosenblatt, D.S.; Jerome-Majewska, L.A. Expression of Mmachc and Mmadhc during Mouse Organogenesis. *Mol. Genet. Metab.* **2011**, *103*, 401–405. [CrossRef] [PubMed]

108. Stucki, M.; Coelho, D.; Suormala, T.; Burda, P.; Fowler, B.; Baumgartner, M.R. Molecular Mechanisms Leading to Three Different Phenotypes in the CblD Defect of Intracellular Cobalamin Metabolism. *Hum. Mol. Genet.* **2012**, *21*, 1410–1418. [CrossRef] [PubMed]

109. Plesa, M.; Kim, J.; Paquette, S.G.; Gagnon, H.; Ng-Thow-Hing, C.; Gibbs, B.F.; Hancock, M.A.; Rosenblatt, D.S.; Coulton, J.W. Interaction between MMACHC and MMADHC, Two Human Proteins Participating in Intracellular Vitamin B12 Metabolism. *Mol. Genet. Metab.* **2010**, *102*, 139–148. [CrossRef] [PubMed]

110. Deme, J.C.; Miousse, I.R.; Plesa, M.; Kim, J.C.; Hancock, M.A.; Mah, W.; Rosenblatt, D.S.; Coulton, J.W. Structural Features of Recombinant MMADHC Isoforms and Their Interactions with MMACHC, Proteins of Mammalian Vitamin B12 Metabolism. *Mol. Genet. Metab.* **2012**, *107*, 352–362. [CrossRef] [PubMed]

111. Froese, D.S.; Kopec, J.; Fitzpatrick, F.; Schuller, M.; McCorvie, T.J.; Chalk, R.; Plessl, T.; Fettelschoss, V.; Fowler, B.; Baumgartner, M.R.; et al. Structural Insights into the MMACHC-MMADHC Protein Complex Involved in Vitamin B12 Trafficking. *J. Biol. Chem.* **2015**, *290*, 29167–29177. [CrossRef]

112. Suormala, T.; Baumgartner, M.R.; Coelho, D.; Zavadakova, P.; Kožich, V.; Koch, H.G.; Berghaüser, M.; Wraith, J.E.; Burlina, A.; Sewell, A.; et al. The CblD Defect Causes Either Isolated or Combined Deficiency of Methylcobalamin and Adenosylcobalamin Synthesis. *J. Biol. Chem.* **2004**, *279*, 42742–42749. [CrossRef]

113. Parini, R.; Furlan, F.; Brambilla, A.; Codazzi, D.; Vedovati, S.; Corbetta, C.; Fedeli, T.; Merinero, B.; Pérez, B.; Ugarte, M. Severe Neonatal Metabolic Decompensation in Methylmalonic Acidemia Caused by CblD Defect. *JIMD Rep.* **2013**, *11*, 133–137.

114. Swanson, D.A.; Liu, M.-L.; Baker, P.J.; Garrett, L.; Stitzel, M.; Wu, J.; Harris, M.; Banerjee, R.; Shane, B.; Brody, L.C. Targeted Disruption of the Methionine Synthase Gene in Mice. *Mol. Cell. Biol.* **2001**, *21*, 1058–1065. [CrossRef]

115. Christensen, E.I.; Birn, H. Megalin and Cubilin: Synergistic Endocytic Receptors in Renal Proximal Tubule. *Am. J. Physiol. Ren. Physiol.* **2001**, *280*, F562–F573. [CrossRef]

116. Menezo, Y.; Elder, K.; Clement, A.; Clement, P. Folic Acid, Folinic Acid, 5 Methyl TetraHydroFolate Supplementation for Mutations That Affect Epigenesis through the Folate and One-Carbon Cycles. *Biomolecules* **2022**, *12*, 197. [CrossRef] [PubMed]

117. Dixon, M.M.; Huang, S.; Matthews, R.G.; Ludwig, M. The Structure of the C-Terminal Domain of Methionine Synthase: Presenting S-Adenosylmethionine for Reductive Methylation of B12. *Structure* **1996**, *4*, 1263–1275. [CrossRef] [PubMed]

118. Chen, L.H.; Liu, M.L.; Hwang, H.Y.; Chen, L.S.; Korenberg, J.; Shane, B. Human Methionine Synthase. CDNA Cloning, Gene Localization, and Expression. *J. Biol. Chem.* **1997**, *272*, 3628–3634. [CrossRef] [PubMed]

119. Drennan, C.L.; Matthews, R.G.; Ludwig, M.L. Cobalamin-Dependent Methionine Synthase: The Structure of a Methylcobalamin-Binding Fragment and Implications for Other B12-Dependent Enzymes. *Curr. Opin. Struct. Biol.* **1994**, *4*, 919–929. [CrossRef]

120. Matthews, R.G.; Sheppard, C.; Goulding, C. Methylenetetrahydrofolate Reductase and Methionine Synthase: Biochemistry and Molecular Biology. *Eur. J. Pediatr.* **1998**, *157*, S54–S59. [CrossRef] [PubMed]

121. Guéant, J.-L.; Caillerez-Fofou, M.; Battaglia-Hsu, S.; Alberto, J.-M.; Freund, J.-N.; Dulluc, I.; Adjalla, C.; Maury, F.; Merle, C.; Nicolas, J.-P.; et al. Molecular and Cellular Effects of Vitamin B12 in Brain, Myocardium and Liver through Its Role as Co-Factor of Methionine Synthase. *Biochimie* **2013**, *95*, 1033–1040. [CrossRef] [PubMed]

122. Gulati, S.; Baker, P.; Li, Y.N.; Fowler, B.; Kruger, W.; Brody, L.C.; Banerjee, R. Defects in Human Methionine Synthase in CblG Patients. *Hum. Mol. Genet.* **1996**, *5*, 1859–1865. [CrossRef] [PubMed]

123. Watkin, D.; Rosenblatt, D.S. Functional Methionine Synthase Deficiency (CblE and CblG): Clinical and Biochemical Heterogeneity. *Am. J. Med. Genet.* **1989**, *34*, 427–434. [CrossRef]

124. Watkins, D.; Ru, M.; Hwang, H.-Y.; Kim, C.D.; Murray, A.; Philip, N.S.; Kim, W.; Legakis, H.; Wai, T.; Hilton, J.F.; et al. Hyperhomocysteinemia Due to Methionine Synthase Deficiency, CblG: Structure of the MTR Gene, Genotype Diversity, and Recognition of a Common Mutation, P1173L. *Am. J. Hum. Genet.* **2002**, *71*, 143–153. [CrossRef]

125. Guéant, J.-L.; Guéant-Rodriguez, R.-M.; Kosgei, V.J.; Coelho, D. Causes and Consequences of Impaired Methionine Synthase Activity in Acquired and Inherited Disorders of Vitamin B$_{12}$ Metabolism. *Crit. Rev. Biochem. Mol. Biol.* **2022**, *57*, 133–155. [CrossRef] [PubMed]

126. Froese, D.S.; Kochan, G.; Muniz, J.R.C.; Wu, X.; Gileadi, C.; Ugochukwu, E.; Krysztofinska, E.; Gravel, R.A.; Oppermann, U.; Yue, W.W. Structures of the Human GTPase MMAA and Vitamin B12-Dependent Methylmalonyl-CoA Mutase and Insight into Their Complex Formation. *J. Biol. Chem.* **2010**, *285*, 38204–38213. [CrossRef] [PubMed]

127. Takahashi-Iñiguez, T.; García-Hernandez, E.; Arreguín-Espinosa, R.; Flores, M.E. Role of Vitamin B12 on Methylmalonyl-CoA Mutase Activity. *J. Zhejiang Univ. Sci. B* **2012**, *13*, 423–437. [CrossRef] [PubMed]

128. Heuberger, K.; Bailey, H.J.; Burda, P.; Chaikuad, A.; Krysztofinska, E.; Suormala, T.; Bürer, C.; Lutz, S.; Fowler, B.; Froese, D.S.; et al. Genetic, Structural, and Functional Analysis of Pathogenic Variations Causing Methylmalonyl-CoA Epimerase Deficiency. *Biochim. Biophys. Acta BBA Mol. Basis Dis.* **2019**, *1865*, 1265–1272. [CrossRef] [PubMed]
129. Gouda, H.; Mascarenhas, R.; Pillay, S.; Ruetz, M.; Koutmos, M.; Banerjee, R. Patient Mutations in Human ATP:Cob(I)Alamin Adenosyltransferase Differentially Affect Its Catalytic versus Chaperone Functions. *J. Biol. Chem.* **2021**, *297*, 101373. [CrossRef] [PubMed]
130. Pratt, J.M. 988. The Chemistry of Vitamin B12. Part II. Photochemical Reactions. *J. Chem. Soc.* **1964**, 5154–5160. [CrossRef]
131. Takahashi-Iñiguez, T.; González-Noriega, A.; Michalak, C.; Flores, M.E. Human MMAA Induces the Release of Inactive Cofactor and Restores Methylmalonyl-CoA Mutase Activity through Their Complex Formation. *Biochimie* **2017**, *142*, 191–196. [CrossRef] [PubMed]
132. Liu, M.-Y.; Liu, T.-T.; Yang, Y.-L.; Chang, Y.-C.; Fan, Y.-L.; Lee, S.-F.; Teng, Y.-T.; Chiang, S.-H.; Niu, D.-M.; Lin, S.-J.; et al. Mutation Profile of the *MUT* Gene in Chinese Methylmalonic Aciduria Patients. *JIMD Rep. Case Res. Rep.* **2012**, *6*, 55–64.
133. Acquaviva, C.; Benoist, J.; Pereira, S.; Callebaut, I.; Koskas, T.; Porquet, D.; Elion, J. Molecular Basis of Methylmalonyl-CoA Mutase Apoenzyme Defect in 40 European Patients Affected by *Mut°* and *Mut*-Forms of Methylmalonic Acidemia: Identification of 29 Novel Mutations in the MUT Gene. *Hum. Mutat.* **2005**, *25*, 167–176. [CrossRef]
134. Willard, H.F.; Rosenberg, L.E. Inherited Methylmalonyl CoA Mutase Apoenzyme Deficiency in Human Fibroblasts. *J. Clin. Investig.* **1980**, *65*, 690–698. [CrossRef]
135. Mineva, E.M.; Sternberg, M.R.; Bailey, R.L.; Storandt, R.J.; Pfeiffer, C.M. Fewer US Adults Had Low or Transitional Vitamin B12 Status Based on the Novel Combined Indicator of Vitamin B12 Status Compared with Individual, Conventional Markers, NHANES 1999–2004. *Am. J. Clin. Nutr.* **2021**, *114*, 1070–1079. [CrossRef] [PubMed]
136. Bailey, R.L.; Carmel, R.; Green, R.; Pfeiffer, C.M.; Cogswell, M.E.; Osterloh, J.D.; Sempos, C.T.; Yetley, E.A. Monitoring of Vitamin B-12 Nutritional Status in the United States by Using Plasma Methylmalonic Acid and Serum Vitamin B-12. *Am. J. Clin. Nutr.* **2011**, *94*, 552–561. [CrossRef] [PubMed]
137. Zhou, Y.; Wang, A.; Yeung, L.F.; Qi, Y.P.; Pfeiffer, C.M.; Crider, K.S. Folate and Vitamin B12 Usual Intake and Biomarker Status by Intake Source in United States Adults Aged ≥19 y: NHANES 2007–2018. *Am. J. Clin. Nutr.* **2023**, *118*, 241–254. [CrossRef] [PubMed]
138. Obeid, R.; Murphy, M.; Solé-Navais, P.; Yajnik, C. Cobalamin Status from Pregnancy to Early Childhood: Lessons from Global Experience. *Adv. Nutr.* **2017**, *8*, 971–979. [CrossRef] [PubMed]
139. Röhrig, G.; Gütgemann, I.; Kolb, G.; Leischker, A. Klinisch-Hämatologisches Bild Des Vitamin-B12-Mangels Im Alter. *Z. Gerontol. Geriatr.* **2018**, *51*, 446–452. [CrossRef] [PubMed]
140. Devi, A.; Rush, E.; Harper, M.; Venn, B. Vitamin B12 Status of Various Ethnic Groups Living in New Zealand: An Analysis of the Adult Nutrition Survey 2008/2009. *Nutrients* **2018**, *10*, 181. [CrossRef]
141. Jajoo, S.S.; Zamwar, U.M.; Nagrale, P. Etiology, Clinical Manifestations, Diagnosis, and Treatment of Cobalamin (Vitamin B12) Deficiency. *Cureus* **2024**, *16*, e52153. [CrossRef]
142. Dali-Youcef, N.; Andres, E. An Update on Cobalamin Deficiency in Adults. *QJM Int. J. Med.* **2009**, *102*, 17–28. [CrossRef]
143. Andrès, E.; Loukili, N.H.; Noel, E.; Kaltenbach, G.; Abdelgheni, M.B.; Perrin, A.E.; Noblet-Dick, M.; Maloisel, F.; Schlienger, J.-L.; Blicklé, J.-F. Vitamin B12 (Cobalamin) Deficiency in Elderly Patients. *Can. Med. Assoc. J.* **2004**, *171*, 251–259. [CrossRef]
144. Lam, J.R.; Schneider, J.L.; Zhao, W.; Corley, D.A. Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B$_{12}$ Deficiency. *JAMA* **2013**, *310*, 2435–2442. [CrossRef]
145. Green, R. Vitamin B12 Deficiency from the Perspective of a Practicing Hematologist. *Blood* **2017**, *129*, 2603–2611. [CrossRef] [PubMed]
146. Lindenbaum, J.; Healton, E.B.; Savage, D.G.; Brust, J.C.M.; Garrett, T.J.; Podell, E.R.; Margell, P.D.; Stabler, S.P.; Allen, R.H. Neuropsychiatric Disorders Caused by Cobalamin Deficiency in the Absence of Anemia or Macrocytosis. *N. Engl. J. Med.* **1988**, *318*, 1720–1728. [CrossRef]
147. Miller, A.; Korem, M.; Almog, R.; Galboiz, Y. Vitamin B12, Demyelination, Remyelination and Repair in Multiple Sclerosis. *J. Neurol. Sci.* **2005**, *233*, 93–97. [CrossRef] [PubMed]
148. Reynolds, E.H.; Linnell, J.C. Vitamin B12 Deficiency, Demyelination, and Multiple Sclerosis. *Lancet* **1987**, *330*, 920. [CrossRef] [PubMed]
149. Troen, A.M.; Shea-Budgell, M.; Shukitt-Hale, B.; Smith, D.E.; Selhub, J.; Rosenberg, I.H. B-Vitamin Deficiency Causes Hyperhomocysteinemia and Vascular Cognitive Impairment in Mice. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 12474–12479. [CrossRef]
150. Carmel, R. Diagnosis and Management of Clinical and Subclinical Cobalamin Deficiencies: Why Controversies Persist in the Age of Sensitive Metabolic Testing. *Biochimie* **2013**, *95*, 1047–1055. [CrossRef]
151. Kulnigg-Dabsch, S. Autoimmune Gastritis. *Wien. Med. Wochenschr.* **2016**, *166*, 424–430. [CrossRef]
152. Lahner, E.; Annibale, B. Pernicious Anemia: New Insights from a Gastroenterological Point of View. *World J. Gastroenterol.* **2009**, *15*, 5121–5128. [CrossRef]
153. Carmel, R. Subclinical Cobalamin Deficiency. *Curr. Opin. Gastroenterol.* **2012**, *28*, 151–158. [CrossRef]
154. Devalia, V.; Hamilton, M.S.; Molloy, A.M.; on Behalf of the British Committee for Standards in Haematology. Guidelines for the Diagnosis and Treatment of Cobalamin and Folate Disorders. *Br. J. Haematol.* **2014**, *166*, 496–513. [CrossRef] [PubMed]
155. Carmel, R.; Agrawal, Y.P. Failures of Cobalamin Assays in Pernicious Anemia. *N. Engl. J. Med.* **2012**, *367*, 385–386. [CrossRef]

156. Miller, J.W.; Garrod, M.G.; Rockwood, A.L.; Kushnir, M.M.; Allen, L.H.; Haan, M.N.; Green, R. Measurement of Total Vitamin B12 and Holotranscobalamin, Singly and in Combination, in Screening for Metabolic Vitamin B12 Deficiency. *Clin. Chem.* **2006**, *52*, 278–285. [CrossRef] [PubMed]

157. Nexo, E.; Hoffmann-Lücke, E. Holotranscobalamin, a Marker of Vitamin B-12 Status: Analytical Aspects and Clinical Utility. *Am. J. Clin. Nutr.* **2011**, *94*, 359S–365S. [CrossRef] [PubMed]

158. Molloy, A.M.; Pangilinan, F.; Mills, J.L.; Shane, B.; O'Neill, M.B.; McGaughey, D.M.; Velkova, A.; Abaan, H.O.; Ueland, P.M.; McNulty, H.; et al. A Common Polymorphism in HIBCH Influences Methylmalonic Acid Concentrations in Blood Independently of Cobalamin. *Am. J. Hum. Genet.* **2016**, *98*, 869–882. [CrossRef] [PubMed]

159. Allen, L.H.; Miller, J.W.; de Groot, L.; Rosenberg, I.H.; Smith, A.D.; Refsum, H.; Raiten, D.J. Biomarkers of Nutrition for Development (BOND): Vitamin B-12 Review. *J. Nutr.* **2018**, *148*, 1995S–2027S. [CrossRef] [PubMed]

160. Fedosov, S.N.; Brito, A.; Miller, J.W.; Green, R.; Allen, L.H. Combined Indicator of Vitamin B12 Status: Modification for Missing Biomarkers and Folate Status and Recommendations for Revised Cut-Points. *Clin. Chem. Lab. Med. CCLM* **2015**, *53*, 1215–1225. [CrossRef] [PubMed]

161. Huemer, M.; Diodato, D.; Schwahn, B.; Schiff, M.; Bandeira, A.; Benoist, J.; Burlina, A.; Cerone, R.; Couce, M.L.; Garcia-Cazorla, A.; et al. Guidelines for Diagnosis and Management of the Cobalamin-related Remethylation Disorders CblC, CblD, CblE, CblF, CblG, CblJ and MTHFR Deficiency. *J. Inherit. Metab. Dis.* **2017**, *40*, 21–48. [CrossRef] [PubMed]

162. Shen, W.; Gao, C.; Cueto, R.; Liu, L.; Fu, H.; Shao, Y.; Yang, W.Y.; Fang, P.; Choi, E.T.; Wu, Q.; et al. Homocysteine-Methionine Cycle Is a Metabolic Sensor System Controlling Methylation-Regulated Pathological Signaling. *Redox Biol.* **2020**, *28*, 101322. [CrossRef] [PubMed]

163. Fowler, B. Homocysteine: Overview of Biochemistry, Molecular Biology, and Role in Disease Processes. *Semin. Vasc. Med.* **2005**, *5*, 77–86. [CrossRef]

164. Hvas, A.-M.; Morkbak, A.L.; Hardlei, T.F.; Nexo, E. The Vitamin B12 Absorption Test, CobaSorb, Identifies Patients Not Requiring Vitamin B12 Injection Therapy. *Scand. J. Clin. Lab. Investig.* **2011**, *71*, 432–438. [CrossRef]

165. Bor, M.V.; Çetin, M.; Aytaç, S.; Altay, C.; Nexo, E. Nonradioactive Vitamin B12 Absorption Test Evaluated in Controls and in Patients with Inherited Malabsorption of Vitamin B12. *Clin. Chem.* **2005**, *51*, 2151–2155. [CrossRef] [PubMed]

166. Hvas, A.-M.; Morkbak, A.L.; Nexo, E. Plasma Holotranscobalamin Compared with Plasma Cobalamins for Assessment of Vitamin B12 Absorption; Optimisation of a Non-Radioactive Vitamin B12 Absorption Test (CobaSorb). *Clin. Chim. Acta* **2007**, *376*, 150–154. [CrossRef] [PubMed]

167. Kurpad, A.V.; Pasanna, R.M.; Hegde, S.G.; Patil, M.; Mukhopadhyay, A.; Sachdev, H.S.; Bhat, K.G.; Sivadas, A.; Devi, S. Bioavailability and Daily Requirement of Vitamin B12 in Adult Humans: An Observational Study of Its Colonic Absorption and Daily Excretion as Measured by [13C]-Cyanocobalamin Kinetics. *Am. J. Clin. Nutr.* **2023**, *118*, 1214–1223. [CrossRef] [PubMed]

168. Garrod, M.G.; Rossow, H.A.; Calvert, C.C.; Miller, J.W.; Green, R.; Buchholz, B.A.; Allen, L.H. ^{14}C-Cobalamin Absorption from Endogenously Labeled Chicken Eggs Assessed in Humans Using Accelerator Mass Spectrometry. *Nutrients* **2019**, *11*, 2148. [CrossRef] [PubMed]

169. Stabler, S.P. Vitamin B$_{12}$ Deficiency. *N. Engl. J. Med.* **2013**, *368*, 2040–2042. [CrossRef] [PubMed]

170. Toh, B.-H. Diagnosis and Classification of Autoimmune Gastritis. *Autoimmun. Rev.* **2014**, *13*, 459–462. [CrossRef] [PubMed]

171. Lahner, E.; Norman, G.L.; Severi, C.; Encabo, S.; Shums, Z.; Vannella, L.; Fave, G.D.; Annibale, B. Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency. *Am. J. Gastroenterol.* **2009**, *104*, 2071–2079. [CrossRef] [PubMed]

172. Froese, D.S.; Gravel, R.A. Genetic Disorders of Vitamin B $_{12}$ Metabolism: Eight Complementation Groups—Eight Genes. *Expert Rev. Mol. Med.* **2010**, *12*, e37. [CrossRef] [PubMed]

173. British Society for Haematology BSH Guidance on B12 Replacement during the COVID-19 Pandemic. 2020. Available online: https://b-s-h.org.uk/media/18275/bsh-guidance-b12-replacement-covid-1901052020finalv.pdf (accessed on 1 June 2024).

174. Gomes, A.P.; Ilter, D.; Low, V.; Endress, J.E.; Fernández-García, J.; Rosenzweig, A.; Schild, T.; Broekaert, D.; Ahmed, A.; Planque, M.; et al. Age-Induced Accumulation of Methylmalonic Acid Promotes Tumour Progression. *Nature* **2020**, *585*, 283–287. [CrossRef]

175. Berkins, S.; Schiöth, H.B.; Rukh, G. Depression and Vegetarians: Association between Dietary Vitamin B6, B12 and Folate Intake and Global and Subcortical Brain Volumes. *Nutrients* **2021**, *13*, 1790. [CrossRef]

176. Sangle, P.; Sandhu, O.; Aftab, Z.; Anthony, A.T.; Khan, S. Vitamin B12 Supplementation: Preventing Onset and Improving Prognosis of Depression. *Cureus* **2020**, *12*, e11169. [CrossRef] [PubMed]

177. Frigo, M.; Cogo, M.G.; Fusco, M.L.; Gardinetti, M.; Frigeni, B. Glutamate and Multiple Sclerosis. *Curr. Med. Chem.* **2012**, *19*, 1295–1299. [CrossRef] [PubMed]

178. Mathew, A.R.; Di Matteo, G.; La Rosa, P.; Barbati, S.A.; Mannina, L.; Moreno, S.; Tata, A.M.; Cavallucci, V.; Fidaleo, M. Vitamin B12 Deficiency and the Nervous System: Beyond Metabolic Decompensation—Comparing Biological Models and Gaining New Insights into Molecular and Cellular Mechanisms. *Int. J. Mol. Sci.* **2024**, *25*, 590. [CrossRef]

179. Alruwaili, M.; Basri, R.; AlRuwaili, R.; Albarrak, A.M.; Ali, N.H. Neurological Implications of Vitamin B12 Deficiency in Diet: A Systematic Review and Meta-Analysis. *Healthcare* **2023**, *11*, 958. [CrossRef] [PubMed]

180. Song, Y.; Quan, M.; Li, T.; Jia, J. Serum Homocysteine, Vitamin B12, Folate, and Their Association with Mild Cognitive Impairment and Subtypes of Dementia. *J. Alzheimers Dis.* **2022**, *90*, 681–691. [CrossRef] [PubMed]

181. Moore, E.; Mander, A.; Ames, D.; Carne, R.; Sanders, K.; Watters, D. Cognitive Impairment and Vitamin B12: A Review. *Int. Psychogeriatr.* **2012**, *24*, 541–556. [CrossRef]

182. Calderón-Ospina, C.A.; Nava-Mesa, M.O. B Vitamins in the Nervous System: Current Knowledge of the Biochemical Modes of Action and Synergies of Thiamine, Pyridoxine, and Cobalamin. *CNS Neurosci. Ther.* **2020**, *26*, 5–13. [CrossRef] [PubMed]

183. Ganguly, P.; Alam, S.F. Role of Homocysteine in the Development of Cardiovascular Disease. *Nutr. J.* **2015**, *14*, 6. [CrossRef]

184. Coppola, A.; Davi, G.; De Stefano, V.; Mancini, F.P.; Cerbone, A.M.; Di Minno, G. Homocysteine, Coagulation, Platelet Function, And Thrombosis. *Semin. Thromb. Hemost.* **2000**, *26*, 243–254. [CrossRef]

185. Ammouri, W.; Tazi, Z.M.; Harmouche, H.; Maamar, M.; Adnaoui, M. Venous Thromboembolism and Hyperhomocysteinemia as First Manifestation of Pernicious Anemia: A Case Series. *J. Med. Case Rep.* **2017**, *11*, 250. [CrossRef]

186. Azzini, E.; Raguzzini, A.; Polito, A. A Brief Review on Vitamin B12 Deficiency Looking at Some Case Study Reports in Adults. *Int. J. Mol. Sci.* **2021**, *22*, 9694. [CrossRef] [PubMed]

187. Ospina-Romero, M.; Cannegieter, S.C.; den Heijer, M.; Doggen, C.J.M.; Rosendaal, F.R.; Lijfering, W.M. Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors. *Am. J. Epidemiol.* **2018**, *187*, 1392–1400. [CrossRef]

188. Çoker, M.; de Klerk, J.B.C.; Poll-The, B.T.; Huijmans, J.G.M.; Duran, M. Plasma Total Odd-chain Fatty Acids in the Monitoring of Disorders of Propionate, Methylmalonate and Biotin Metabolism. *J. Inherit. Metab. Dis.* **1996**, *19*, 743–751. [CrossRef] [PubMed]

189. Gomes, A.P.; Ilter, D.; Low, V.; Drapela, S.; Schild, T.; Mullarky, E.; Han, J.; Elia, I.; Broekaert, D.; Rosenzweig, A.; et al. Altered Propionate Metabolism Contributes to Tumour Progression and Aggressiveness. *Nat. Metab.* **2022**, *4*, 435–443. [CrossRef] [PubMed]

190. Hu, C.; Ye, M.; Bai, J.; Liu, P.; Lu, F.; Chen, J.; Yu, P.; Chen, T.; Shi, X.; Tang, Q. Methylmalonic Acid Promotes Colorectal Cancer Progression via Activation of Wnt/β-Catenin Pathway Mediated Epithelial–Mesenchymal Transition. *Cancer Cell Int.* **2023**, *23*, 131. [CrossRef]

191. Loedin, A.K.; Speijer, D. Is There a Carcinogenic Risk Attached to Vitamin B$_{12}$ Deficient Diets and What Should We Do About It? Reviewing the Facts. *Mol. Nutr. Food Res.* **2021**, *65*, 2000945. [CrossRef]

192. Obeid, R. High Plasma Vitamin B12 and Cancer in Human Studies: A Scoping Review to Judge Causality and Alternative Explanations. *Nutrients* **2022**, *14*, 4476. [CrossRef]

193. Haghighat, G.; Khajeh-Mehrizi, A.; Ranjbar, H. Evaluation of Serum Vitamin B12 Levels in Patients with Colon and Breast Cancer: A Case-Control Study. *Int. J. Hematol. Oncol. Stem Cell Res.* **2023**, *17*, 240–244. [CrossRef] [PubMed]

194. Zhang, S.M.; Willett, W.C.; Selhub, J.; Hunter, D.J.; Giovannucci, E.L.; Holmes, M.D.; Colditz, G.A.; Hankinson, S.E. Plasma Folate, Vitamin B6, Vitamin B12, Homocysteine, and Risk of Breast Cancer. *JNCI J. Natl. Cancer Inst.* **2003**, *95*, 373–380. [CrossRef]

195. Wu, W.; Kang, S.; Zhang, D. Association of Vitamin B6, Vitamin B12 and Methionine with Risk of Breast Cancer: A Dose–Response Meta-Analysis. *Br. J. Cancer* **2013**, *109*, 1926–1944. [CrossRef]

196. Matejcic, M.; de Batlle, J.; Ricci, C.; Biessy, C.; Perrier, F.; Huybrechts, I.; Weiderpass, E.; Boutron-Ruault, M.C.; Cadeau, C.; His, M.; et al. Biomarkers of Folate and Vitamin B12 and Breast Cancer Risk: Report from the EPIC Cohort. *Int. J. Cancer* **2017**, *140*, 1246–1259. [CrossRef] [PubMed]

197. Tseng, L.T.-L.; Lin, C.-L.; Pan, K.-H.; Tzen, K.-Y.; Su, M.-J.; Tsai, C.-T.; Li, Y.-H.; Li, P.-C.; Chiang, F.-T.; Chang, S.C.; et al. Single Allele Lmbrd1 Knockout Results in Cardiac Hypertrophy. *J. Formos. Med. Assoc.* **2018**, *117*, 471–479. [CrossRef]

198. Barth, A.S.; Kuner, R.; Buness, A.; Ruschhaupt, M.; Merk, S.; Zwermann, L.; Kääb, S.; Kreuzer, E.; Steinbeck, G.; Mansmann, U.; et al. Identification of a Common Gene Expression Signature in Dilated Cardiomyopathy Across Independent Microarray Studies. *J. Am. Coll. Cardiol.* **2006**, *48*, 1610–1617. [CrossRef]

199. Jonnalagadda, D.; Kihara, Y.; Groves, A.; Ray, M.; Saha, A.; Ellington, C.; Lee-Okada, H.-C.; Furihata, T.; Yokomizo, T.; Quadros, E.V.; et al. FTY720 Requires Vitamin B12-TCN2-CD320 Signaling in Astrocytes to Reduce Disease in an Animal Model of Multiple Sclerosis. *Cell Rep.* **2023**, *42*, 113545. [CrossRef]

200. Munoz, M.; Henderson, M.; Haber, M.; Norris, M. Role of the MRP1/ABCC1 Multidrug Transporter Protein in Cancer. *IUBMB Life* **2007**, *59*, 752–757. [CrossRef] [PubMed]

201. Li, F.; Mao, C.; Yeh, S.; Xin, J.; Wang, P.; Shi, Q.; Ming, X. Combinatory Therapy of MRP1-Targeted Photoimmunotherapy and Liposomal Doxorubicin Promotes the Antitumor Effect for Chemoresistant Small Cell Lung Cancer. *Int. J. Pharm.* **2022**, *625*, 122076. [CrossRef] [PubMed]

202. Pietz, H.L.; Abbas, A.; Johnson, Z.L.; Oldham, M.L.; Suga, H.; Chen, J. A Macrocyclic Peptide Inhibitor Traps MRP1 in a Catalytically Incompetent Conformation. *Proc. Natl. Acad. Sci. USA* **2023**, *120*, e2220012120. [CrossRef] [PubMed]

203. Hanssen, K.M.; Haber, M.; Fletcher, J.I. Targeting Multidrug Resistance-Associated Protein 1 (MRP1)-Expressing Cancers: Beyond Pharmacological Inhibition. *Drug Resist. Updates* **2021**, *59*, 100795. [CrossRef]

204. Alhaji, J.H. Vitamin B12 Deficiency in Patients with Diabetes on Metformin: Arab Countries. *Nutrients* **2022**, *14*, 2046. [CrossRef]

205. Bell, D.S.H. Metformin-induced Vitamin B12 Deficiency Can Cause or Worsen Distal Symmetrical, Autonomic and Cardiac Neuropathy in the Patient with Diabetes. *Diabetes Obes. Metab.* **2022**, *24*, 1423–1428. [CrossRef]

206. Infante, M.; Leoni, M.; Caprio, M.; Fabbri, A. Long-Term Metformin Therapy and Vitamin B12 Deficiency: An Association to Bear in Mind. *World J. Diabetes* **2021**, *12*, 916–931. [CrossRef] [PubMed]

207. Bauman, W.A.; Shaw, S.; Jayatilleke, E.; Spungen, A.M.; Herbert, V. Increased Intake of Calcium Reverses Vitamin B12 Malabsorption Induced by Metformin. *Diabetes Care* **2000**, *23*, 1227–1231. [CrossRef]

208. Out, M.; Kooy, A.; Lehert, P.; Schalkwijk, C.A.; Stehouwer, C.D.A. Long-Term Treatment with Metformin in Type 2 Diabetes and Methylmalonic Acid: Post Hoc Analysis of a Randomized Controlled 4.3 Year Trial. *J. Diabetes Complicat.* **2018**, 32, 171–178. [CrossRef] [PubMed]

209. Kovatcheva, M.; Melendez, E.; Chondronasiou, D.; Pietrocola, F.; Bernad, R.; Caballe, A.; Junza, A.; Capellades, J.; Holguín-Horcajo, A.; Prats, N.; et al. Vitamin B12 Is a Limiting Factor for Induced Cellular Plasticity and Tissue Repair. *Nat. Metab.* **2023**, 5, 1911–1930. [CrossRef]